var data={"title":"Fentanyl: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fentanyl: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6188?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">see &quot;Fentanyl: Drug information&quot;</a> and <a href=\"topic.htm?path=fentanyl-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fentanyl: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50847583\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada, in collaboration with manufacturers, will update the Canadian labelling of all prescription opioid products to include the following:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation for a daily opioid threshold dose for the management of chronic noncancer, nonpalliative pain (which aims to reduce risks of adverse events and overdoses associated with higher doses of opioids);</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation to limit the quantity of opioids prescribed for acute pain (which aims to reduce the duration of use and associated risks of developing dependence and substance use disorder); and</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Clarification of warnings, including those for special populations such as pregnant women and patients with a history of dependence or substance use disorder.</p></li></ul>\n        <p style=\"text-indent:0em;\">Health Canada has prioritized product tables for updating based on risk. The labelling updates for all prescription opioids are expected to be completed in January 2019.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65362a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708780\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life-threatening respiratory depression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious, life-threatening, or fatal respiratory depression has occurred with use of fentanyl, including following use in opioid non-tolerant patients and improper dosing. Monitor for respiratory depression, especially during initiation of fentanyl or following a dose increase. The substitution of fentanyl buccal, intranasal, lozenge, or sublingual for any other fentanyl product may result in fatal overdose. Due to the risk of respiratory depression, fentanyl buccal, intranasal, lozenge, and sublingual are contraindicated in the management of acute or postoperative pain including headache/migraine and in opioid non-tolerant patients; fentanyl transdermal is contraindicated for use as an as-needed analgesic, in nonopioid tolerant patients, in acute pain, and in postoperative pain. Only the patient should activate Ionsys dosing.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Addiction, abuse, and misuse:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fentanyl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing fentanyl, and monitor all patients regularly for the development of these behaviors and conditions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Accidental exposure:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Accidental exposure of even one dose of fentanyl, especially by children, can result in a fatal overdose of fentanyl. Death has been reported in children who have accidentally ingested transmucosal immediate-release fentanyl products. Deaths due to a fatal overdose of fentanyl have occurred when children and adults were accidentally exposed to fentanyl transdermal patch. Strict adherence to the recommended handling and disposal instructions is of the utmost importance to prevent accidental exposure. Fentanyl must be kept out of reach of children.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cytochrome P450 3A4 Interaction:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The concomitant use of fentanyl with all cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in fentanyl plasma concentration. Monitor patients receiving fentanyl and any CYP3A4 inhibitor or inducer.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neonatal opioid withdrawal syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prolonged use of fentanyl during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with benzodiazepines or other CNS depressants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of fentanyl and benzodiazepine or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of medication errors (buccal, intranasal, lozenge, sublingual):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Substantial differences exist in the pharmacokinetic profile of fentanyl buccal, intranasal, lozenge, and sublingual compared with other fentanyl products that result in clinically important differences in the extent of absorption of fentanyl that could result in fatal overdose. When prescribing, do not convert patients on a mcg-per-mcg basis from any other fentanyl products to fentanyl buccal, intranasal, lozenge, or sublingual. When dispensing, do not substitute a fentanyl buccal, intranasal, lozenge, or sublingual prescription for other fentanyl products.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">REMS program:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Buccal, intranasal, lozenge, sublingual: Because of the risk for misuse, abuse, addiction, and overdose, fentanyl buccal, intranasal, lozenge, and sublingual are available only through a restricted program required by the FDA, called a Risk Evaluation and Mitigation Strategy (REMS). Under the Transmucosal Immediate Release Fentanyl (TIRF) REMS Access Program, outpatients, health care providers who prescribe to outpatients, pharmacies, and distributors must enroll in the program. Further information is available at http://www.TIRFREMSaccess.com or by calling 1-866-822-1483.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal iontophoretic system (Ionsys): For use only in patients in the hospital. Discontinue treatment with before patients leave the hospital. Because of the risk of respiratory depression from accidental exposure, Ionsys is available through a restricted program called the Ionsys REMS Program. Healthcare facilities that dispense Ionsys must be certified in this program and comply with the REMS requirements.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Exposure to heat (Duragesic only):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Exposure of the fentanyl application site and surrounding area to direct external heat sources, such as heating pads or electric blankets, heat or tanning lamps, sunbathing, hot baths, saunas, hot tubs, and heated water beds may increase fentanyl absorption and has resulted in fatal overdose of fentanyl. Warn patients to avoid exposing the application site and surrounding area to direct external heat sources.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170610\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Abstral;</li>\n      <li>Actiq;</li>\n      <li>Duragesic;</li>\n      <li>Fentora;</li>\n      <li>Ionsys;</li>\n      <li>Lazanda;</li>\n      <li>Onsolis [DSC];</li>\n      <li>Sublimaze;</li>\n      <li>Subsys</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170611\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Abstral;</li>\n      <li>Duragesic;</li>\n      <li>Fentora</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052734\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Analgesic, Narcotic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">General Anesthetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442526\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses should be titrated to appropriate effects; wide range of doses exist, dependent upon desired degree of analgesia/anesthesia, clinical environment, patient's status, and presence of opioid tolerance. Lower initial doses are recommended for nonventilated patients (WHO 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Analgesia:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">International Evidence-Based Group for Neonatal Pain recommendations (Anand 2001): Opioid-naive:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent doses: Slow IV push: 0.5 to 3 mcg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: 0.5 to 2 mcg/kg/<b>hour </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">WHO Guidelines for Pediatric Pain (WHO 2012): Opioid-naive:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent doses: Slow IV push: Initial: 1 to 2 mcg/kg/dose; may repeat every 2 to 4 hours, titrate dose to effectiveness</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Initial IV bolus: Slow IV push: 1 to 2 mcg/kg, then 0.5 to 1 mcg/kg/<b>hour</b>; titrate upward; usual range: 1 to 3 mcg/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: Intermittent doses: Some centers have used the following: Slow IV push: 1 to 4 mcg/kg/dose; may repeat every 2 to 4 hours (Nelson 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Continuous analgesia/sedation; mechanically ventilated patient:</b> Limited data available: Initial IV bolus: 1 to 2 mcg/kg, then 0.5 to 1 mcg/kg/<b>hour</b>; titrate carefully to effect. Dosing based on a trial of 20 neonates ventilated for respiratory distress syndrome; mean required dose was age-dependent: GA &lt;34 weeks (n=12): 0.64 mcg/kg/<b>hour</b> and for GA &ge;34 weeks (n=8): 0.75 mcg/kg/<b>hour</b> (Roth 1991).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Continuous analgesia/sedation during ECMO:</b> Limited data available: Initial IV bolus: 5 to 10 mcg/kg slow IV push over 10 minutes, then 1 to 5 mcg/kg/<b>hour</b>; titrate carefully to effect; tolerance may develop; higher doses (up to 20 mcg/kg/<b>hour</b>) may be needed by day 6 of ECMO (Arnold 1991; Leuschen 1993).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endotracheal intubation:</b> Limited data available: IV: 1 to 4 mcg/kg slow IV push (Cloherty 2012; Kumar 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052726\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">see &quot;Fentanyl: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses should be titrated to appropriate effects; wide range of doses exist, dependent upon desired degree of analgesia/anesthesia, clinical environment, patient's status, and presence of opioid tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Pediatric patients &lt;18 years of age:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <span style=\"text-decoration: underline\">\n          <b>Acute, short-term uses:</b></span></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute pain:</b> Opioid-na&iuml;ve:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: Limited data available: IV: Initial: 1 to 2 mcg/kg/dose; may repeat at 2 to 4 hour intervals; in opioid-tolerant or younger infants, titration to higher doses may be required (up to 4 mcg/kg/dose) (Hegenbarth 2008; Nelson 1996; WHO 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: Limited data available in &lt;2 years of age: IV: Initial: 1 to 2 mcg/kg/dose; may repeat at 30- to 60-minute intervals; in opioid-tolerant children, titration to higher doses may be required. <b>Note:</b> Usual adolescent starting dose is 25 to 50 mcg (Hegenbarth 2008; Nelson 1996; WHO 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &lt;18 years: <b>Note:</b> After the first dose, if severe pain persists and adverse effects are minimal at the time of expected peak effect, may repeat dose (APS 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;50 kg: Initial: IV: 0.5 to 1 mcg/kg/dose may repeat every 1 to 2 hours although some patients may require more frequent dosing (eg, 30-minute intervals) (APS 2008; Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;50 kg: Initial: IV: 25 to 50 mcg every 1 to 2 hours although some patients may require more frequent dosing (eg, 30-minute intervals) (APS 2008; Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesia for minor procedures/sedation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: Limited data available in &lt;2 years of age: IM, IV: 1 to 2 mcg/kg/dose; administer 3 minutes before the procedure; maximum dose: 50 mcg/dose; may repeat <sup>1</sup>/<sub>2</sub> original dose every 3 to 5 minutes if necessary; titrate to effect (Cramton 2012; Krauss 2006; Zeltzer 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &lt;18 years: IV: 0.5 to 1 mcg/kg/dose; may repeat after 30 to 60 minutes; or 25 to 50 mcg, repeat full dose in 5 minutes if needed, may repeat 4 to 5 times with 25 mcg at 5-minute intervals if needed. <b>Note:</b> Higher doses are used for major procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal (using parenteral preparation): Limited data available: Infants and Children weighing &ge;10 kg: Intranasal: 1.5 mcg/kg once (maximum: 100 mcg/dose); reported range: 1 to 2 mcg/kg; some studies that used an initial dose of 1.5 mcg/kg allowed for additional incremental doses of 0.3 to 0.5 mcg/kg to be administered every 5 minutes, not to exceed a total dose of 3 mcg/kg depending on pain type and severity (Borland 2002; Borland 2005; Borland 2007; Chung 2010; Cole 2009; Crellin 2010; Herd 2009; Manjushree 2002; Saunders 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anesthesia, general; adjunct:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 12 years: IM, IV: 2 to 3 mcg/kg/dose; <b>N<b>ote:</b></b> An IV should be in place with general anesthesia so the IM route is rarely used but still maintained as an option in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &lt;18 years: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low dose: 0.5 to 2 mcg/kg/dose depending on the indication</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate dose: Initial: 2 to 20 mcg/kg/dose; Maintenance (bolus or infusion): 1 to 2 mcg/kg/<b>hour</b>. Discontinuing fentanyl infusion 30 to 60 minutes prior to the end of surgery will usually allow adequate ventilation upon emergence from anesthesia. For &quot;fast-tracking&quot; and early extubation following major surgery, total fentanyl doses are limited to 10 to 15 mcg/kg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High dose: 20 to 50 mcg/kg/dose; <b>Note:</b> High-dose fentanyl as an adjunct to general anesthesia is rarely used, but is still described in the manufacturer's label.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anesthesia, general without additional anesthetic agents:</b> Adolescents &lt;18 years: IV: 50 to 100 mcg/kg/dose with O<sub>2</sub> and skeletal muscle relaxant</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anesthesia, regional; adjunct: </b>Adolescents &lt;18 years: IM, IV: 50 to 100 mcg; <b>Note:</b> An IV should be in place with regional anesthesia so the IM route is rarely used but still maintained as an option in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Continuous analgesia/sedation: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: Limited data available in &lt;2 years of age: Initial IV bolus: 1 to 2 mcg/kg followed by continuous IV infusion at initial rate: 1 mcg/kg/<b>hour</b>; titrate to effect; usual range: 1 to 3 mcg/kg/<b>hour</b>; some patients may require higher rates (5 mcg/kg/<b>hour)</b> (WHO 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &lt;18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;50 kg: Initial IV bolus: 0.5 to 2 mcg/kg followed by continuous IV infusion at initial rate: 0.5 to 2 mcg/kg/<b>hour</b> based on expert recommendations for children and pediatric patients &le;50 kg (APS 2008; Berde 2002; WHO 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;50 kg: Initial IV bolus: 25 to 100 mcg/dose followed by continuous IV infusion at initial rate: 25 to 200 mcg/<b>hour</b> based on expert recommendations for pediatric patients and experience in adult patients (APS 2008; Berde 2002; Liu 2003; Peng 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Endotracheal intubation, emergent: </b>Limited data available: Infants and Children: IV: 1 to 5 mcg/kg/dose (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Preoperative sedation: </b>Adolescents &lt;18 years: IM, IV: 50 to 100 mcg administered 30 to 60 minutes prior to surgery or slow IV: 25 to 50 mcg given shortly before induction (Barash 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Patient-controlled analgesia (PCA):</b> Limited data available: Children &ge;5 years and Adolescents &lt;18 years; opioid-na&iuml;ve: <b>Note:</b> PCA has been used in children as young as 5 years; however, clinicians need to assess children 5 to 8 years of age to determine if they are able to use the PCA device correctly. All patients should receive an initial loading dose of an analgesic (to attain adequate control of pain) before starting PCA for maintenance. Adjust doses, lockouts, and limits based on required loading dose, age, state of health, and presence of opioid tolerance. Use lower end of dosing range for opioid-na&iuml;ve. Assess patient and pain control at regular intervals and adjust settings if needed (APS 2008): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient weight &le;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Usual concentration: Determined by weight; some centers use the following:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &lt;12 kg: 10 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 12 to 30 kg: 25 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &gt;30 kg: 50 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Demand dose: Usual initial: 0.5 to 1 mcg/kg/dose; usual range: 0.5 to 1 mcg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lockout: Usual initial: 5 doses/hour</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lockout interval: Range: 6 to 8 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Usual basal rate: 0 to 0.5 mcg/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient weight &gt;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Usual concentration: 50 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Demand dose: Usual initial: 20 mcg; usual range: 10 to 50 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lockout interval: Usual initial: 6 minutes; usual range: 5 to 8 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Usual basal rate: &le;50 mcg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <span style=\"text-decoration: underline\">\n        <b>\n          <i>Chronic uses or opioid-tolerant patients (eg, cancer pain):</i></b></span></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic pain, moderate to severe (opioid-tolerant):</b> Transdermal patch: Duragesic: Children &ge;2 years and Adolescents &lt;18 years who are opioid-tolerant receiving at least 60 mg oral morphine equivalents per day: <b>Note:</b> Discontinue or taper all other around-the-clock or extended release opioids when initiating therapy with fentanyl transdermal patch:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 25 mcg<b>/hour</b> system or higher based on previous opioid dosing. To convert patients from oral or parenteral opioids to transdermal patch, a 24-hour analgesic requirement should be calculated (based on prior opioid use). Using the following tables, the appropriate initial dose can be determined. The initial fentanyl dosage may be approximated from the 24-hour morphine dosage equivalent and titrated to minimize adverse effects and provide analgesia. Substantial interpatient variability exists in relative potency. Therefore, it is safer to underestimate a patient&rsquo;s daily fentanyl requirement and provide breakthrough pain relief with rescue medication (eg, immediate release opioid) than to overestimate requirements. With the initial application, the absorption of transdermal fentanyl requires several hours to reach plateau; therefore, transdermal fentanyl is inappropriate for management of acute pain. Change patch every 72 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion from continuous infusion of fentanyl: In patients who have adequate pain relief with a fentanyl infusion, fentanyl may be converted to transdermal dosing at a rate equivalent to the intravenous rate. Based on experience in adults, a two-step taper of the infusion to be completed over 12 hours may be considered (Kornick 2001) after the patch is applied. The infusion is decreased to 50% of the original rate 6 hours after the application of the first patch, and subsequently discontinued twelve hours after application.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Titration: Short-acting agents may be required until analgesic efficacy is established and/or as supplements for &ldquo;breakthrough&rdquo; pain. The amount of supplemental doses should be closely monitored. Appropriate dosage increases may be based on daily supplemental dosage using the ratio of 45 mg/24 hours of oral morphine to a 12.5 mcg/hour increase in fentanyl dosage</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Frequency of adjustment<i>: </i>The dosage should not be titrated more frequently than every 3 days after the initial dose or every 6 days thereafter. Titrate dose based on the daily dose of supplemental opioids required by the patient on the second or third day of the initial application. <b>Note:</b> Upon discontinuation, ~17 hours are required for a 50% decrease in fentanyl levels.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Frequency of application<i>: </i>The majority of patients may be controlled on every 72-hour administration; however, a small number of adult patients have required every 48-hour administration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Discontinuation: When discontinuing transdermal fentanyl and not converting to another opioid, use a gradual downward titration, such as decreasing the dose by 50% every 6 days, to reduce the possibility of withdrawal symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dose conversion guidelines for transdermal fentanyl from other opioids (see tables).</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> The conversion factors in these tables are only to be used for the conversion from current opioid therapy to Duragesic patch. Conversion factors in this table cannot be used to convert from Duragesic to another opioid (doing so may lead to fatal overdose due to overestimation of the new opioid). <b>These are not tables of equianalgesic doses</b>.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption>\n        <b>Dose Conversion Guidelines: Recommended Initial Duragesic Dose Based Upon Daily Oral Morphine Dose<sup>a,b</sup></b></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Oral 24-Hour Morphine</p>\n            <p style=\"text-indent:0em;\">(mg/day)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Duragesic Dose<sup>c</sup></p>\n            <p style=\"text-indent:0em;\">(mcg/hour)</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>a</sup>The table should NOT be used to convert from transdermal fentanyl (Duragesic) to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>b</sup>Recommendations are based on US product labeling for Duragesic.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>c</sup>Pediatric patients initiating therapy on a 25 mcg/hour Duragesic system should be opioid-tolerant and receiving at least 60 mg oral morphine equivalents per day.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 to 134</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">135 to 224</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">225 to 314</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">315 to 404</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">405 to 494</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">125</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">495 to 584</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">585 to 674</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">175</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">675 to 764</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">765 to 854</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">225</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">855 to 944</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">945 to 1,034</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">275</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,035 to 1,124</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300</p></td></tr></tbody></table>\n    \n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Dose Conversion Guidelines<sup>a,b</sup></caption>\n      <col></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Current Analgesic</p></th>\n          <th colspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">Daily Dosage</p>\n            <p style=\"text-indent:0em;\">(mg/day)</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>a</sup>The table should NOT be used to convert from transdermal fentanyl (Duragesic) to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>b</sup>Recommendations are based on US product labeling for Duragesic.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Morphine (IM/IV)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 to 22</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">23 to 37</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">38 to 52</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">53 to 67</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Oxycodone (oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 67</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">67.5 to 112</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">112.5 to 157</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">157.5 to 202</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Codeine (oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150 to 447</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">-</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">-</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">-</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Hydromorphone (oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 17</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">17.1 to 28</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">28.1 to 39</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">39.1 to 51</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Hydromorphone (IV)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.5 to 3.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.5 to 5.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.7 to 7.9</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 10</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Meperidine (IM)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75 to 165</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">166 to 278</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">279 to 390</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">391 to 503</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Methadone (oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 to 44</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">45 to 74</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75 to 104</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">105 to 134</p></td></tr>\n        <tr>\n          <td></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Fentanyl transdermal recommended dose (mcg/hour) </b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>25 mcg/hour</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>50 mcg/hour</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>75 mcg/hour</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>100 mcg/hour</b></p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cancer</b>\n      <b> pain; breakthrough:</b> Transmucosal lozenge: Actiq: Adolescents &ge;16 years: <b>Note:</b> For patients who are tolerant to and currently receiving opioid therapy for persistent cancer pain; dosing should be individually titrated to provide adequate analgesia with minimal side effects. <b>Patients must remain on around-the-clock opioids during use</b><b>.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: 200 mcg (consumed over 15 minutes) for all patients; if after 30 minutes from the start of the lozenge (ie, 15 minutes following the completion of the lozenge), the pain is unrelieved, a second 200 mcg dose may be given over 15 minutes. A maximum of 1 additional dose can be given per pain episode; <b>must wait at least 4 hours before treating another episode.</b> To limit the number of units in the home during titration, only prescribe an initial titration supply of six 200 mcg lozenges. <b>Note:</b> Do not convert patients from any other fentanyl product to Actiq on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 200 mcg; individually titrate to provide adequate analgesia while minimizing adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose titration: Dose titration should be done if patient requires more than 1 dose/breakthrough pain episode for several consecutive episodes. From the initial dose, closely follow patients and modify the dose until patient reaches a dose providing adequate analgesia using a single dosage unit per breakthrough cancer pain episode. If signs/symptoms of excessive opioid effects (eg, respiratory depression) occur, immediately remove the dosage unit from the patient&rsquo;s mouth, dispose of properly, and reduce subsequent doses. If adequate relief is not achieved 15 minutes after completion of the first dose (ie, 30 minutes after the start of the lozenge), only 1 additional lozenge of the same strength may be given for that episode; <b>must wait at least 4 hours before treating another episode.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Once titrated to an effective dose, patients should generally use a single dosage unit per breakthrough pain episode. During any pain episode, if adequate relief is not achieved 15 minutes after completion of the first dose (ie, 30 minutes after the start of the lozenge), only 1 additional lozenge of the same strength may be given over 15 minutes for that episode; <b>must wait at least 4 hours before treating another episode</b>. Consumption should be limited to &le;4 units per day (once an effective breakthrough dose is found). If adequate analgesia is <b>not </b>provided after treating several episodes of breakthrough pain using the same dose, increase dose to next highest lozenge strength (initially dispense no more than 6 units of the new strength). Consider increasing the around-the-clock opioid therapy in patients experiencing &gt;4 breakthrough pain episodes per day and have their long-term opioid re-evaluated. If signs/symptoms of excessive opioid effects (eg, respiratory depression) occur, immediately remove the dosage unit from the patient&rsquo;s mouth, dispose of properly, and reduce subsequent doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <span style=\"text-decoration: underline\">Adolescents 18 years and Adults:</span></i> Note:</b> Ranges listed may not represent the maximum doses that may be required in some patients. Doses and dosage intervals should be titrated to pain relief/prevention. Monitor vital signs routinely. Single IM doses have duration of 1 to 2 hours; single IV doses last 0.5 to 1 hour.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgery:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Premedication: IM, slow IV: 50 to 100 mcg administered 30 to 60 minutes prior to surgery <b>or</b> slow IV: 25 to 50 mcg given shortly before induction (Barash 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adjunct to general anesthesia: Slow IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low dose: 1 to 2 mcg/<b>kg</b> depending on the indication (Miller 2010); additional maintenance doses are generally not needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate dose (fentanyl plus a sedative/hypnotic): Initial: 2 to 4 mcg/<b>kg</b>; Maintenance (bolus or infusion): 25 to 50 mcg every 15 to 30 minutes or 0.5 to 2 mcg/kg/<b>hour</b>. Discontinuing fentanyl infusion 30 to 60 minutes prior to the end of surgery will usually allow adequate ventilation upon emergence from anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High dose (opioid anesthesia): 4 to 20 mcg/<b>kg</b> bolus then 2 to 10 mcg/kg/<b>hour</b> (Miller 2010); <b>Note:</b> High-dose fentanyl (ie, 20 to 50 mcg/kg) is rarely used, but is still described in the manufacturer&rsquo;s label. The concept of fast-tracking and early extubation following cardiac surgery has essentially replaced high-dose fentanyl anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adjunct to regional anesthesia: 50 to 100 mcg IM or slow IV over 1 to 2 minutes. <b>Note:</b> An IV should be in place with regional anesthesia so the IM route is rarely used but still maintained as an option in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Postoperative recovery: IM, slow IV: 50 to 100 mcg every 1 to 2 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pain management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Postoperative pain, acute:</b> Transdermal device (Ionsys): Apply one device to chest or upper outer arm only. Only the patient may activate the device (40 mcg dose of fentanyl per activation; maximum: 6 doses per hour). Only one device may be applied at a time for up to 24 hours or 80 doses, whichever comes first. May be used for a maximum of 72 hours, with each subsequent device applied to a different skin site. If inadequate analgesia is achieved with one device, either provide additional supplemental analgesic medication or replace with an alternate analgesic medication. Refer to manufacturer&rsquo;s labeling for activation instructions.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> For hospital use only by patients under medical supervision and direction and only after patients have been titrated to an acceptable level of analgesia using another opioid analgesic.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Severe pain:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Intermittent dosing:</i> IM, IV: Slow IV: 25 to 35 mcg (based on ~70 kg patient) <b>or</b> 0.35 to 0.5 mcg/kg every 30 to 60 minutes as needed (SCCM [Barr 2013]). <b>Note:</b> After the first dose, if severe pain persists and adverse effects are minimal at the time of expected peak effect (eg, ~5 minutes after IV administration), may repeat dose (APS 2008). In addition, since the duration of activity with IV administration is 30 to 60 minutes, more frequent administration may be necessary when administered by this route.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Patient-controlled analgesia (PCA) (APS 2008; Miller 2010): Opioid-naive:</i> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Usual concentration: 10 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Demand dose: Usual: 10 to 20 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Lockout interval: 4 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Usual basal rate: &le;50 mcg/hour. <b>Note:</b> Continuous basal infusions are not recommended for initial programming and should rarely be used; consider limiting infusion rate to 10 mcg/hour if used (Grass 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cancer pain; breakthrough:</b> Transmucosal: Opioid-tolerant patients: For patients who are tolerant to and currently receiving opioid therapy for persistent cancer pain; dosing should be individually titrated to provide adequate analgesia with minimal side effects. Dose titration should be done if patient requires more than 1 dose/breakthrough pain episode for several consecutive episodes. Patients experiencing &gt;4 breakthrough pain episodes/day should have the dose of their long-term opioid re-evaluated. <b>Patients must remain on around-the-clock opioids during use.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lozenge (eg, Actiq): <b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Actiq on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 200 mcg; individually titrate to provide adequate analgesia while minimizing adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial dose: 200 mcg (consumed over 15 minutes) for all patients; if after 30 minutes from the start of the lozenge (ie, 15 minutes following the completion of the lozenge), the pain is unrelieved, a second 200 mcg dose may be given over 15 minutes. A maximum of 1 additional dose can be given per pain episode; <b>must wait at least 4 hours before treating another episode</b>. To limit the number of units in the home during titration, only prescribe an initial titration supply of six 200 mcg lozenges.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dose titration: From the initial dose, closely follow patients and modify the dose until patient reaches a dose providing adequate analgesia using a single dosage unit per breakthrough cancer pain episode. If signs/symptoms of excessive opioid effects (eg, respiratory depression) occur, immediately remove the dosage unit from the patient&rsquo;s mouth, dispose of properly, and reduce subsequent doses. If adequate relief is not achieved 15 minutes after completion of the first dose (ie, 30 minutes after the start of the lozenge), only 1 additional lozenge of the same strength may be given for that episode; <b>must wait at least 4 hours before treating another episode.</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: Once titrated to an effective dose, patients should generally use a single dosage unit per breakthrough pain episode. During any pain episode, if adequate relief is not achieved 15 minutes after completion of the first dose (ie, 30 minutes after the start of the lozenge), only 1 additional lozenge of the same strength may be given over 15 minutes for that episode; <b>must wait at least 4 hours before treating another episode</b>. Consumption should be limited to &le;4 units per day (once an effective breakthrough dose is found). If adequate analgesia is <b>not </b>provided after treating several episodes of breakthrough pain using the same dose, increase dose to next highest lozenge strength (initially dispense no more than 6 units of the new strength). Consider increasing the around-the-clock opioid therapy in patients experiencing &gt;4 breakthrough pain episodes per day. If signs/symptoms of excessive opioid effects (eg, respiratory depression) occur, immediately remove the dosage unit from the patient&rsquo;s mouth, dispose of properly, and reduce subsequent doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Buccal film (eg, Onsolis): <b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Onsolis on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 200 mcg; individually titrate to provide adequate analgesia while minimizing adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial dose: 200 mcg for all patients; if after 30 minutes pain is unrelieved, the patient may use an alternative rescue medication as directed by their health care provider. Do <b>not</b> redose with Onsolis within an episode; buccal film should only be used once per breakthrough cancer pain episode. <b>Must wait at least 2 hours before treating another episode with buccal film.</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dose titration: If titration required, increase dose in 200 mcg increments once per episode using multiples of the 200 mcg film (for doses up to 800 mcg); do not redose within a single episode of breakthrough pain and separate single doses by &ge;2 hours. During titration, do not exceed 4 simultaneous applications of the 200 mcg films (800 mcg) (when using multiple films, do not place on top of each other; film may be placed on both sides of mouth); if &gt;800 mcg required, treat next episode with one 1,200 mcg film (maximum dose: 1,200 mcg). Once maintenance dose is determined, all other unused films should be disposed of and that strength (using a single film) should be used. During any pain episode, if adequate relief is not achieved after 30 minutes following buccal film application, a rescue medication (as determined by health care provider) may be used.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: Determined dose applied as a single film once per episode and separated by &ge;2 hours (dose range: 200 to 1,200 mcg); limit to 4 applications per day. Consider increasing the around-the-clock opioid therapy in patients experiencing &gt;4 breakthrough pain episodes per day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Buccal tablets (Fentora): <b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Fentora on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 100 mcg; individually titrate to provide adequate analgesia while minimizing adverse effects. For patients previously using the transmucosal lozenge (Actiq), the initial dose should be selected using the conversions listed; see <i>Conversion from lozenge (Actiq) to buccal tablet (Fentora)</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial dose: 100 mcg for all patients unless patient already using Actiq; see <i>Conversion from lozenge (Actiq) to buccal tablet (Fentora)</i>; if after 30 minutes pain is unrelieved, a second 100 mcg dose may be administered (maximum of 2 doses per breakthrough pain episode). <b>Must wait at least 4 hours before treating another episode with Fentora buccal tablet.</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dose titration: If titration required, 100 mcg dose may be increased to 200 mcg using two 100 mcg tablets (one on each side of mouth) with the next breakthrough pain episode. If 200 mcg dose is not successful, patient can use four 100 mcg tablets (two on each side of mouth) with the next breakthrough pain episode. If titration requires &gt;400 mcg per dose, titrate using 200 mcg tablets; do not use more than 4 tablets simultaneously (maximum single dose: 800 mcg). During any pain episode, if adequate relief is not achieved after 30 minutes following buccal tablet application, a second dose of same strength per breakthrough pain episode may be used. <b>Must wait at least 4 hours before treating another episode with Fentora buccal tablet.</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: Following titration, the effective maintenance dose using 1 tablet of the appropriate strength should be administered once per episode; if after 30 minutes pain is unrelieved, may administer a second dose of the same strength. <b>Must wait &ge;4 hours before treating another episode with Fentora buccal tablet.</b> Limit to 4 applications per day. Consider increasing the around-the-clock opioid therapy in patients experiencing &gt;4 breakthrough pain episodes per day. Once an effective maintenance dose has been established, the buccal tablet may be administered sublingually (alternate route). To prevent confusion, patient should only have one strength available at a time. Once maintenance dose is determined, all other unused tablets should be disposed of and that strength (using a single tablet) should be used. Using more than four buccal tablets at a time has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from lozenge (Actiq) to buccal tablet</i> (Fentora):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Lozenge dose 200 to 400 mcg: Initial buccal tablet dose is 100 mcg; may titrate using multiples of 100 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Lozenge dose 600 to 800 mcg: Initial buccal tablet dose is 200 mcg; may titrate using multiples of 200 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Lozenge dose 1,200 to 1,600 mcg: Initial buccal tablet dose is 400 mcg (using two 200 mcg tablets); may titrate using multiples of 200 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nasal spray (Lazanda): <b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Lazanda on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 100 mcg; individually titrate to provide adequate analgesia while minimizing adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initial dose:</i> 100 mcg (one 100 mcg spray in one nostril) for all patients; if after 30 minutes pain is unrelieved, an alternative rescue medication may be used as directed by their health care provider. <b>Must wait at least 2 hours before treating another episode with Lazanda nasal spray.</b> However, for the next pain episode, increase to a higher dose using the recommended dose titration steps.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dose titration:</i> If titration required, increase to a higher dose using the recommended titration steps. (<b>Note: <b>Must wait at least 2 hours before treating another episode with nasal spray.)</b></b> Dose titration steps: If no relief with 100 mcg dose, increase to 200 mcg dose per episode (one 100 mcg spray in each nostril); if no relief with 200 mcg dose, increase to 300 mcg dose per episode (alternating one 100 mcg spray in right nostril, one 100 mcg spray in left nostril, and one 100 mcg spray in the right nostril); if no relief with 300 mcg dose, increase to 400 mcg per episode (one 400 mcg spray in one nostril <b>or</b> two 100 mcg sprays in each nostril); if no relief with 400 mcg dose, increase to 600 mcg dose per episode (one 300 mcg spray in each nostril); if no relief with 600 mcg dose, increase to 800 mcg dose per episode (one 400 mcg spray in each nostril). <b>Note:</b> Single doses &gt;800 mcg have not been evaluated. There are no data supporting the use of a combination of dose strengths. Avoid use of a combination of dose strengths to treat an episode.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Maintenance dose:</i> Once maintenance dose for breakthrough pain episode has been determined, use that dose for subsequent episodes. For pain that is not relieved after 30 minutes of Lazanda administration or if a separate breakthrough pain episode occurs within the 2 hour window before the next Lazanda dose is permitted, a rescue medication may be used. Limit Lazanda use to &le;4 episodes of breakthrough pain per day. If patient is experiencing &gt;4 breakthrough pain episodes/day, consider increasing the around-the-clock, long-acting opioid therapy; if long-acting opioid therapy dose is altered, re-evaluate and retitrate Lazanda dose as needed. If response to maintenance dose changes (increase in adverse reactions or alterations in pain relief), dose readjustment may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sublingual spray (Subsys): <b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Subsys on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 100 mcg; individually titrate to provide adequate analgesia while minimizing adverse effects. For patients previously using the transmucosal lozenge (Actiq), the initial dose should be selected using the conversions listed; see <i>Conversion from lozenge (Actiq) to sublingual spray (Subsys)</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initial dose:</i> 100 mcg for all patients unless patient already using Actiq; see <i>Conversion from lozenge (Actiq) to sublingual spray (Subsys)</i> If pain is unrelieved, one additional 100 mcg dose may be given 30 minutes after administration of the first dose. A maximum of two doses can be given per breakthrough pain episode. <b>Must wait at least 4 hours before treating another episode with sublingual spray</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dose titration:</i> If titration required, titrate to a dose that provides adequate analgesia (with tolerable side effects) using the following titration steps: If no relief with 100 mcg dose, increase to 200 mcg dose per episode (one 200 mcg unit); if no relief with 200 mcg dose, increase to 400 mcg per episode (one 400 mcg unit); if no relief with 400 mcg dose, increase to 600 mcg dose per episode (one 600 mcg unit); if no relief with 600 mcg dose, increase to 800 mcg dose per episode (one 800 mcg unit); if no relief with 800 mcg dose, increase to 1,200 mcg dose per episode (two 600 mcg units); if no relief with 1,200 mcg dose, increase to 1,600 mcg per episode (two 800 mcg units). During dose titration, if breakthrough pain unrelieved 30 minutes after Subsys administration, 1 additional dose using the same strength may be administered (maximum: 2 doses per breakthrough pain episode); <b>patient must wait 4 hours before treating another breakthrough pain episode with sublingual spray.</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Maintenance dose:</i> Once maintenance dose for breakthrough pain episode has been determined, use that dose for subsequent episodes. If occasional episodes of unrelieved breakthrough pain occur following 30 minutes of Subsys administration, one additional dose using the same strength may be administered (maximum: Two doses per breakthrough pain episode); patient must wait 4 hours before treating another breakthrough pain episode with Subsys. Once maintenance dose is determined, limit Susbsys use to &le;4 episodes of breakthrough pain per day. If response to maintenance dose changes (increase in adverse reactions or alterations in pain relief), dose readjustment may be necessary. If patient is experiencing &gt;4 breakthrough pain episodes/day, consider increasing the around-the-clock, long-acting opioid therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from lozenge (Actiq) to sublingual spray (Subsys):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Lozenge dose 200 to 400 mcg: Initial sublingual spray dose is 100 mcg; may titrate using multiples of 100 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Lozenge dose 600 to 800 mcg: Initial sublingual spray dose is 200 mcg; may titrate using multiples of 200 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Lozenge dose 1,200 to 1,600 mcg: Initial sublingual spray dose is 400 mcg; may titrate using multiples of 400 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sublingual tablet (Abstral): <b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Abstral on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 100 mcg (except Actiq); individually titrate to provide adequate analgesia while minimizing adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initial dose:</i> 100 mcg for all patients unless patient already using Actiq; see <i>Conversion from lozenge (Actiq) to sublingual tablet (Abstral)</i>; if pain is unrelieved, a second dose may be given 30 minutes after administration of the first dose. A maximum of two doses can be given per breakthrough pain episode<b>. Must wait at least 2 hours before treating another episode.</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dose titration:</i> If titration required, increase in 100 mcg increments (up to 400 mcg) over consecutive breakthrough episodes. If titration requires &gt;400 mcg/dose, increase in increments of 200 mcg, starting with 600 mcg dose and titrating up to 800 mcg. During titration, patients may use multiples of 100 mcg and/or 200 mcg tablets for any single dose; do not exceed 4 tablets at one time; safety and efficacy of doses &gt;800 mcg have not been evaluated. During dose titration, if breakthrough pain unrelieved 30 minutes after sublingual tablet administration, one additional dose using the same strength may be administered (maximum: 2 doses per breakthrough pain episode). <b>Patient must wait 2 hours before treating another breakthrough pain episode with sublingual tablet.</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Maintenance dose:</i> Once maintenance dose for breakthrough pain episode has been determined, use only one tablet in the appropriate strength per episode. If pain is unrelieved with maintenance dose, a second dose may be given after 30 minutes; maximum of 2 doses/episode of breakthrough pain; separate treatment of subsequent episodes by &ge;2 hours; limit treatment to &le;4 breakthrough episodes/day. Consider increasing the around-the-clock, long-acting opioid therapy in patients experiencing &gt;4 breakthrough pain episodes/day; if long-acting opioid therapy dose altered, re-evaluate and retitrate Abstral dose as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from lozenge (Actiq) to sublingual tablet (Abstral)</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Lozenge dose 200 mcg: Initial sublingual tablet dose is 100 mcg; may titrate using multiples of 100 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Lozenge dose 400 to 1,200 mcg: Initial sublingual tablet dose is 200 mcg; may titrate using multiples of 200 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Lozenge dose 1,600 mcg: Initial sublingual tablet dose is 400 mcg; may titrate using multiples of 400 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic pain management (opioid-tolerant patients only): </b>Transdermal patch: Discontinue or taper all other around-the-clock or extended release opioids when initiating therapy with fentanyl transdermal patch.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: To convert patients from oral or parenteral opioids to transdermal patch, a 24-hour analgesic requirement should be calculated (based on prior opioid use). Using the following tables, the appropriate initial dose can be determined. The initial fentanyl dosage may be approximated from the 24-hour morphine dosage equivalent and titrated to minimize adverse effects and provide analgesia. Substantial interpatient variability exists in relative potency. Therefore, it is safer to underestimate a patient&rsquo;s daily fentanyl requirement and provide breakthrough pain relief with rescue medication (eg, immediate release opioid) than to overestimate requirements. With the initial application, the absorption of transdermal fentanyl requires several hours to reach plateau; therefore, transdermal fentanyl is inappropriate for management of acute pain. Change patch every 72 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion from continuous infusion of fentanyl: In patients who have adequate pain relief with a fentanyl infusion, fentanyl may be converted to transdermal dosing at a rate equivalent to the intravenous rate. A two-step taper of the infusion to be completed over 12 hours has been recommended (Kornick 2001) after the patch is applied. The infusion is decreased to 50% of the original rate six hours after the application of the first patch, and subsequently discontinued 12 hours after application.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Titration: Short-acting agents may be required until analgesic efficacy is established and/or as supplements for &ldquo;breakthrough&rdquo; pain. The amount of supplemental doses should be closely monitored. Appropriate dosage increases may be based on daily supplemental dosage using the ratio of 45 mg/24 hours of oral morphine to a 12.5 mcg/hour increase in fentanyl dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Frequency of adjustment: The dosage should not be titrated more frequently than every 3 days after the initial dose or every 6 days thereafter. Titrate dose based on the daily dose of supplemental opioids required by the patient on the second or third day of the initial application. <b>Note:</b> Upon discontinuation, ~17 hours are required for a 50% decrease in fentanyl levels.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Frequency of application: The majority of patients may be controlled on every 72-hour administration; however, a small number of adult patients require every 48-hour administration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Discontinuation: When discontinuing transdermal fentanyl and not converting to another opioid, use a gradual downward titration, such as decreasing the dose by 50% every 6 days, to reduce the possibility of withdrawal symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dose conversion guidelines for transdermal fentanyl (see tables).</i> <b>Note:</b> The conversion factors in these tables are only to be used for the conversion from current opioid therapy to Duragesic. Conversion factors in this table cannot be used to convert from Duragesic to another opioid (doing so may lead to fatal overdose due to overestimation of the new opioid). These are not tables of equianalgesic doses.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Dose Conversion Guidelines: Recommended Initial Duragesic Dose Based Upon Daily Oral Morphine Dose<sup>a,b</sup></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Oral 24-Hour Morphine</p>\n            <p style=\"text-indent:0em;\">(mg/day)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Duragesic Dose<sup>c</sup></p>\n            <p style=\"text-indent:0em;\">(mcg/hour)</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>a</sup>The table should NOT be used to convert from transdermal fentanyl (Duragesic) to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>b</sup>Recommendations are based on US product labeling for Duragesic.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>c</sup>Pediatric patients initiating therapy on a 25 mcg/hour Duragesic system should be opioid-tolerant and receiving at least 60 mg oral morphine equivalents per day.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 to 134</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">135 to 224</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">225 to 314</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">315 to 404</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">405 to 494</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">125</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">495 to 584</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">585 to 674</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">175</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">675 to 764</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">765 to 854</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">225</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">855 to 944</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">945 to 1,034</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">275</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,035 to 1,124</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300</p></td></tr></tbody></table>\n    \n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Dose Conversion Guidelines<sup>a,b</sup></caption>\n      <col></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Current Analgesic</p></th>\n          <th colspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">Daily Dosage</p>\n            <p style=\"text-indent:0em;\">(mg/day)</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>a</sup>The table should NOT be used to convert from transdermal fentanyl (Duragesic) to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>b</sup>Recommendations are based on US product labeling for Duragesic.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Morphine (IM/IV)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 to 22</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">23 to 37</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">38 to 52</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">53 to 67</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Oxycodone (oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 67</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">67.5 to 112</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">112.5 to 157</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">157.5 to 202</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Codeine (oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150 to 447</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">-</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">-</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">-</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Hydromorphone (oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 17</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">17.1 to 28</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">28.1 to 39</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">39.1 to 51</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Hydromorphone (IV)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.5 to 3.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.5 to 5.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.7 to 7.9</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 10</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Meperidine (IM)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75 to 165</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">166 to 278</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">279 to 390</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">391 to 503</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Methadone (oral)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 to 44</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">45 to 74</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75 to 104</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">105 to 134</p></td></tr>\n        <tr>\n          <td></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td>\n          <td align=\"center\"></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Fentanyl transdermal recommended dose (mcg/hour) </b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>25 mcg/hour</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>50 mcg/hour</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>75 mcg/hour</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>100 mcg/hour</b></p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the following guidelines have been used by some clinicians (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents: The following assumes dosages of 0.5 to 2 mcg/kg/dose or 1 to 5 mcg/kg/<b>hour</b> in normal renal function: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis: Administer 50% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): Administer 50% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): Administer 75% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal (device): Adolescents &ge;18 years and Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); fentanyl pharmacokinetics may be altered in renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal (patch): Pediatric patients &ge;2 years and Adults: Degree of impairment (ie, CrCl) not defined in manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate impairment: Initial: Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment: Use not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transmucosal (buccal film/tablet, sublingual spray/tablet, lozenge) and nasal spray: Adolescents &ge;18 years and Adults: Although fentanyl pharmacokinetics may be altered in renal disease, fentanyl can be used successfully in the management of breakthrough cancer pain. Use with caution; reduce initial dose and titrate to reach clinical effect with careful monitoring of patients, especially those with severe renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal (device): Adolescents &ge;18 years and Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); fentanyl pharmacokinetics may be altered in hepatic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal (patch): Pediatric patients &ge;2 years and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate impairment: Initial: Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment: Use not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transmucosal (buccal film/tablet, sublingual spray/tablet, lozenge) and nasal spray: Adolescents &ge;18 years and Adults: Although fentanyl pharmacokinetics may be altered in hepatic disease, fentanyl can be used successfully in the management of breakthrough cancer pain. Use with caution; reduce initial dose and titrate to reach clinical effect with careful monitoring of patients, especially those with severe hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170583\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Film, for buccal application, as citrate [strength expressed as base]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Onsolis: 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s); 1200 mcg (30s) [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution, as citrate [strength expressed as base, preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublimaze: 100 mcg/2 mL (2 mL); 250 mcg/5 mL (5 mL); 1000 mcg/ 20 mL (20 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 100 mcg/2 mL (2 mL); 250 mcg/5 mL (5 mL); 500 mcg/10 mL (10 mL); 1000 mcg/ 20 mL (20 mL); 2500 mcg/50 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liquid, sublingual, as base [spray]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Subsys: 100 mcg (30s); 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s) [contains dehydrated ethanol 63.6%, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lozenge, oral, as citrate [strength expressed as base, transmucosal]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Actiq: 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s); 1200 mcg (30s); 1600 mcg (30s) [contains sugar 2 g/lozenge; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 200 mcg (30s); 400 mcg (30s); 600 mcg (30s); 800 mcg (30s); 1200 mcg (30s); 1600 mcg (30s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch, transdermal, as base:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duragesic: 12 [delivers 12.5 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm<sup>2</sup>; 5 cm<sup>2</sup>]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duragesic: 25 [delivers 25 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm<sup>2</sup>; 10 cm<sup>2</sup>]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duragesic: 50 [delivers 50 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm<sup>2</sup>; 20 cm<sup>2</sup>]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duragesic: 75 [delivers 75 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm<sup>2</sup>; 30 cm<sup>2</sup>]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duragesic: 100 [delivers 100 mcg/hr] (5s) [contains ethanol 0.1 mL/10 cm<sup>2; </sup>40 cm<sup>2</sup>]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ionsys: 40 mcg/actuation (6s) [iontophoretic transdermal system]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 12 [delivers 12.5 mcg/hr] (5s); 25 [delivers 25 mcg/hr] (5s); 37.5 [delivers 37.5 mcg/hr]; 50 [delivers 50 mcg/hr] (5s); 62.5 [delivers 62.5 mcg/hr]; 75 [delivers 75 mcg/hr] (5s); 87.5 [delivers 87.5 mcg/hr] (5s); 100 [delivers 100 mcg/hr] (5s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder, for prescription compounding, as citrate: USP: 100% (1 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, intranasal, as citrate [strength expressed as base, spray]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lazanda: 100 mcg/spray (5 mL); 300 mcg/spray (5 mL); 400 mcg/spray (5 mL) [delivers 8 metered sprays]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, for buccal application, as citrate [strength expressed as base]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fentora: 100 mcg (28s); 200 mcg (28s); 400 mcg (28s); 600 mcg (28s); 800 mcg (28s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, sublingual, as citrate [strength expressed as base]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Abstral: 100 mcg (12s, 32s); 200 mcg (12s, 32s); 300 mcg (12s, 32s); 400 mcg (12s, 32s); 600 mcg (32s); 800 mcg (32s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170567\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Injection, lozenge, patch</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28106456\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Onsolis: Reformulated product FDA approved August 2015; availability anticipated in the first half of 2018.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170661\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50183666\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">As a requirement of the REMS program, access is restricted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transmucosal immediate-release fentanyl products (eg, sublingual tablets and spray, oral lozenges, buccal tablets and soluble film, intranasal) are only available through the Transmucosal Immediate-Release Fentanyl (TIRF) REMS ACCESS program. Enrollment in the program is required for outpatients, prescribers for outpatient use, pharmacies (inpatient and outpatient), and distributors. Enrollment is not required for inpatient administration (eg, hospitals, hospices, long-term care facilities), inpatients, and prescribers who prescribe to inpatients. Further information is available at 1-866-822-1483 or at www.TIRFREMSaccess.com</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Effective December, 2011, individual REMs programs for TIRF products were combined into a single access program (TIRF REMS Access). Prescribers and pharmacies that were enrolled in at least one individual REMS program for these products will automatically be transitioned to the single access program.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874432\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Abstral: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022510s015lbl.pdf#page=29&amp;token=hSs1Eazyf+PPIFqHUHqt7Rx7EzEIIMJVvMb5euj3IZNBkEtTNuIcbYAnyP/Znjt+p4+CfjxreohMc+/zp4t1lN7jMXe1BfvBKowHE4PmrMtvfEt1q416e7o7vtNxvxPl&amp;TOPIC_ID=13298\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022510s015lbl.pdf#page=29</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Actiq: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020747s043s044lbl.pdf#page=21&amp;token=HN1Y7iaI/cfwN0CEMuhl60FCjkhA5QGAwZVHV8hlo6MNxyaKbWD6dM6d1G/Jr6xfL3Y8pqAWIHeE0mNDkupOYh2Swn/AH5dHQqC5Vix8dFP8fQ+h1YiTEJEiKubT32pG&amp;TOPIC_ID=13298\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020747s043s044lbl.pdf#page=21</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duragesic: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019813s072s073lbl.pdf#page=48&amp;token=7ZzLF+C7R96qd+gtCVwN2M+JMxhUBgOqvOTzTEIWQ1U5ZH65UNzdgSIcG1wPlB8SAZtrzEAylgfTg7jTwpuyynBNYN5Zx19iWRozZQL72ibCcfdGlMpp2ekFcYIbyObE&amp;TOPIC_ID=13298\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019813s072s073lbl.pdf#page=48</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fentora: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021947s019lbl.pdf#page=20&amp;token=sgue1VRxbi89Ggz7GyoGb6HTtAtcgb+mY0GLaPEoKnyaAkcNZuI4VWU0HaUvvqqpRyKkCLlGPWN6+sZKcFTtwqWiPZr0tw7k4dWOM0LERHT+mF/C8/hzyjf5FwGyNXc8&amp;TOPIC_ID=13298\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021947s019lbl.pdf#page=20</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lazanda: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022569s024lbl.pdf#page=35&amp;token=rCuM9yf0Q5zu9voZMjQfPRhajnsn9tWo3hZU/RrAlTt3j74C184qWW4cE7DthHvNnNqL2sl48rM+1SuP2JgIJZmPqIruD76PFevNfDOx7QbWApyOCurZkuiqYeQCtpDR&amp;TOPIC_ID=13298\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022569s024lbl.pdf#page=35</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Onsolis: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022266s017s018lbl.pdf#page=32&amp;token=uV9lFmKDxTSyBGHQ5zKMG2kn6tzpSAfjLKdcE79iVIzgsDr6hlJSEmgjGOxY0edeHUKhlKht1SfjSnitHyi4UmbqeKUJbOUHIgPeqFP9KmYItrsH4VClS4vxTFMb8tk+&amp;TOPIC_ID=13298\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022266s017s018lbl.pdf#page=32</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Subsys: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202788s016lbl.pdf#page=38&amp;token=6Y5kOx6/9dAbqNB3qpFkVY0T/8Ru6wysVStG0u/Vc7fZ2As111CgRFLet0k2ApCmJLFWzDwFbfqL5jv0r0LxqIciMUH6MwzcrCTNQV6Q5etWWU4WCmlF3wUJpBBvyJ2T&amp;TOPIC_ID=13298\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202788s016lbl.pdf#page=38</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052739\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: Administer by intermittent infusion very slowly over 15 to 30 minutes or by continuous IV infusion (ISMP 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b></b>Infants, Children, Adolescents, and Adults: Administer by slow IV push over 3 to 5 minutes or by continuous infusion. Larger bolus doses (&gt;5 mcg/kg) should be given by slow IV push over 5 to 10 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Transdermal device (eg, Ionsys): </b>Always wear gloves when handling the device. Avoid contact with synthetic materials (such as carpeted flooring) while assembling and avoid exposing the device to electronic security systems. Prior to administration, clip excessive hair from application site if necessary (do not shave); clean the site with alcohol and let dry; do not use soaps, lotions, or other agents. Apply one device to healthy, unbroken/intact, nonirritated, and nonirradiated skin on the chest or upper outer arm only. Allow only the patient to self-administer doses; each on-demand dose is delivered over a 10-minute period. Each device operates up to 24 hours or 80 doses, whichever comes first. After 24 hours have elapsed, or 80 doses have been delivered, the device will not deliver any additional doses; if the patient tries to initiate a dose, the device will ignore the dose request. Ionsys may be used for a maximum of 72 hours, with each subsequent device applied to a different skin site. Refer to manufacturer&rsquo;s labeling for complete activation, administration, and removal instructions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Transdermal patch:</b> Apply to nonhairy, clean, dry, nonirritated, intact skin of the flat area of front or back of upper torso, flank area, or upper arm; apply to upper back in young children or in people with cognitive impairment to decrease the potential of the patient removing the patch. Monitor the adhesion of the system closely in children. Clip hair prior to application, do <b>not</b> shave area; prior to application, skin may be cleaned with clear water (do not use soaps, lotions, alcohol, oils, or other substances which may irritate the skin); allow skin to dry thoroughly prior to application. Apply patch immediately after removing from package; firmly press in place and hold for at least 30 seconds; change patch every 72 hours; remove old patch before applying new patch; do not apply new patch to same place as old patch; wash hands after applying patch. If there is difficulty with patch adhesion, the edges of the system may be taped in place with first-aid tape; if difficulty with adhesion persists, an adhesive film dressing (eg, Bioclusive, Tegaderm) may be applied over the system. If patch falls off before 72 hours, a new patch may be applied to a different skin site. Dispose of any used or unused patches by removing patch from protective pouch and liner, fold adhesive ends together and flush patch down toilet immediately. Do not flush pouch or protective liner as such items can be discarded in the trash.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Transdermal patch is a membrane-controlled system; do <b>not</b> cut the patch to deliver partial doses; do <b>not</b> use patches that are cut, damaged, or leaking; do <b>not</b> use if seal of package is broken; rate of drug delivery may be significantly increased if patch is cut, damaged, or leaking and result in absorption of a potentially fatal dose; reservoir contents and adhesion may be affected if cut; if partial dose is needed, surface area of patch can be blocked proportionally using adhesive bandage (Lee 1997). Do <b>not</b> use soap, alcohol, or other solvents to remove transdermal gel if it accidentally touches skin as they may increase transdermal absorption; use copious amounts of water. Avoid exposing application site to external heat sources (eg, electric blanket, heating pad, heat lamp, tanning lamp, sauna, heated water bed, hot tub, hot baths, sunbathing). Dispose of properly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Transmucosal products:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Buccal film (eg, Onsolis):</b> Foil overwrap should be removed just prior to administration. Prior to placing film, wet inside of cheek using tongue or by rinsing with water. Place film inside mouth with the pink side of the unit against the inside of the moistened cheek. With finger, press the film against cheek and hold for 5 seconds. The film should stick to the inside of cheek after 5 seconds. The film should be left in place until it dissolves (usually within 15 to 30 minutes after application). Liquids may be consumed after 5 minutes of application. Food can be eaten after film dissolves. If using more than one film simultaneously (during titration period), apply films on either side of mouth (do not apply on top of each other). Do not chew or swallow film. Do not cut or tear the film. All patients must initiate therapy using the 200 mcg film. To dispose of film; remove foil overwrap from any unused, unneeded films and dispose by flushing down the toilet.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Buccal tablet (eg, Fentora):</b> Blister package should be opened just prior to administration. Peel back the blister backing to expose the tablet; do not push tablet through the blister (damage to the tablet may occur). Administer tablet immediately after removal from blister. Place entire tablet in the buccal cavity (above a rear molar, between the upper cheek and gum) or under the tongue (for maintenance doses only); should dissolve in about 14 to 25 minutes. If remnants remain after 30 minutes they may be swallowed with a glass of water. Use alternate side of mouth for subsequent doses. Do not break, split, suck, crush, chew, or swallow whole tablet (this will result in decreased effect). If excessive opioid effects appear before tablet is completely dissolved (eg, dizziness, sedation, nausea), instruct patient to rinse mouth with water and spit remaining pieces of tablet into sink or toilet immediately; rinse the sink or flush toilet to dispose of tablet particles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intranasal:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Solution (injectable product):</b> Pediatric patients &ge;10 kg: If congested, suction nostrils prior to administration. Using a 50 mcg/mL solution, administer half of the dose to each nostril using an atomizer such as the MAD&reg; Nasal Drug delivery device or drip into the nostril slowly with a syringe; higher concentrations (150 mcg/mL and 300 mcg/mL) have been studied to prevent excess volume administration and decrease leakage, but comparative trials have not been performed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Nasal spray (eg, Lazanda):</b> Prior to initial use, prime device by spraying 4 sprays into the provided pouch (the counting window will show a green bar when the bottle is ready for use). Insert nozzle a short distance into the nose (~<sup>1</sup>/<sub>2</sub> inch or 1 cm) and point towards the bridge of the nose (while closing off the other nostril using one finger). Press on finger grips until a &ldquo;click&rdquo; sound is heard and the number in the counting window advances by one. The &ldquo;click&rdquo; sound and dose counter are the only reliable methods for ensuring a dose has been administered (spray is not always felt on the nasal mucosa). Patient should remain seated for at least 1 minute following administration. Do not blow nose for &ge;30 minutes after administration. Wash hands before and after use. If not used within 5 days, re-prime by spraying once. There are 8 full therapeutic sprays in each bottle; do not continue to use bottle after &ldquo;8&rdquo; sprays have been used. Dispose of bottle and contents if it has been &ge;60 days since first use. Before disposal, all unopened or partially used bottles must be completely emptied by spraying the contents into the provided pouch. After &ldquo;8&rdquo; therapeutic sprays has been reached on the counter, patients should continue to spray an additional four sprays into the pouch to ensure that any residual fentanyl has been expelled (an audible click will no longer be heard and the counter will not advance beyond &ldquo;8&rdquo;). The empty bottle and the sealed pouch must be put into the child-resistant container before placing in the trash. Wash hands with soap and water immediately after handling the pouch. If the pouch is lost, another one can be ordered by the patient or caregiver by calling 1-866-458-6389.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Oral lozenge (eg, Actiq):</b> Oral: Foil overwrap should be removed just prior to administration, patient should place the unit in mouth between cheek and lower gum; occasionally move lozenge from one side of the mouth to the other and allow it to dissolve. Do not bite or chew lozenge; consume lozenge over 15 minutes. Remove handle after lozenge is consumed. Early removal should be considered if the patient has achieved an adequate response and/or shows signs of respiratory depression. After consumption of a complete unit, the handle may be disposed of in a trash container that is out of the reach of children. For a partially consumed unit, or a unit that still has any drug matrix remaining on the handle, the handle should be placed under hot running tap water until the drug matrix has dissolved. Special child-resistant containers are available to temporarily store partially consumed units that cannot be disposed of immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sublingual spray (eg, Subsys):</b> Open sealed blister unit with scissors immediately prior to administration. Contents of unit should be sprayed into mouth under the tongue. Dispose of unit immediately after use, place used unit into one of the provided white disposal bags. After sealing appropriately, discard in the trash. Dispose of any unused units as soon as no longer needed. Prior to disposal, empty all the medicine into the provided charcoal-lined disposal pouch. The disposal pouch should then be placed into the white disposal bag, sealed appropriately, and discarded in the trash.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sublingual tablet (eg, Abstral):</b> Remove from the blister unit immediately prior to administration. Place tablet directly under the tongue on the floor of the mouth and allow to completely dissolve; do not chew, suck, or swallow. Do not eat or drink anything until tablet is completely dissolved. In patients with a dry mouth, water may be used to moisten the buccal mucosa just before administration. All patients must initiate therapy using the 100 mcg tablet. To dispose of sublingual tablets; remove any unused tablets from the blister cards and dispose by flushing down the toilet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472638\" class=\"block uicn drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 10 <b>mcg</b>/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472637\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 10 <b>mcg</b>/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170604\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Do not store above 25&deg;C (77&deg;F); do not freeze. Protect from light. Bottle should be stored in the provided child-resistant container when not in use and kept out of the reach of children at all times.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal device, transdermal patch, transmucosal (buccal film, buccal tablet, lozenge, sublingual spray, sublingual tablet): Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect transmucosal products from freezing and moisture. Keep all products out of the reach of children.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052738\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Relief of pain; preoperative medication; adjunct to general or regional anesthesia (FDA approved in ages &ge;2 years and adults); has also been used for sedation and intranasally for analgesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch (eg, Duragesic): Treatment of persistent, moderate-to-severe chronic pain in opioid-tolerant patients who are currently receiving opioids (FDA approved in ages &ge;2 years and adults); see <b>Note</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal device (eg, Ionsys): Short-term management of acute postoperative pain requiring opioid analgesia in the hospital (FDA approved in &ge;18 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transmucosal products:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal film (eg, Onsolis): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opioids for persistent cancer pain (FDA approved in ages &ge;18 years and adults); see <b>Note</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal tablet (eg, Fentora): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opioids for persistent cancer pain (FDA approved in ages &ge;18 years and adults); see <b>Note</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nasal spray (eg, Lazanda): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opioids for persistent cancer pain (FDA approved in ages &ge;18 years and adults); see <b>Note</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral lozenge (eg, Actiq): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opioids for persistent cancer pain (FDA approved in ages &ge;16 years and adults); see <b>Note</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual spray (eg, Subsys): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opioids for persistent cancer pain (FDA approved in ages &ge;18 years and adults); see <b>Note</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablet (eg, Abstral): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opioids for persistent cancer pain (FDA approved in ages &ge;18 years and adults); see <b>Note</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Patients are considered opioid-tolerant if they are receiving around-the-clock opioids at a dose of at least 60 mg/day of oral morphine, 25 mcg/hour of transdermal fentanyl, 30 mg/day of oral oxycodone, 8 mg/day of oral hydromorphone, 25 mg/day of oral oxymorphone or an equivalent dose of another opioid for 1 week or longer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170670\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FentaNYL may be confused with alfentanil, SUFentanil</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fentanyl transdermal system patches: Leakage of fentanyl gel from the patch has been reported; patch may be less effective; do not use. Thoroughly wash any skin surfaces coming into direct contact with gel with water (do not use soap). May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fentanyl transdermal system patches: </p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Dosing of transdermal fentanyl patches may be confusing. Transdermal fentanyl patches should always be prescribed in mcg/hour, not size. Patch dosage form of Duragesic-12 actually delivers 12.5 mcg/hour of fentanyl. Use caution, as orders may be written as &ldquo;Duragesic 12.5&rdquo; which can be erroneously interpreted as a 125 mcg dose.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Patches should be stored and disposed of with care to avoid accidental exposure to children. The FDA has issued numerous safety advisories to warn users of the possible consequences (including hospitalization and death) of inappropriate storage or disposal of patches.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Abstral, Actiq, Fentora, Onsolis, and Subsys are not interchangeable; do not substitute doses on a mcg-per-mcg basis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170667\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial fibrillation, bigeminy, cardiac arrhythmia, chest pain, deep vein thrombosis, edema, hypertension, hypotension, myocardial infarction, orthostatic hypotension, palpitations, peripheral edema, pulmonary embolism (nasal spray), sinus tachycardia, syncope, tachycardia, vasodilatation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams, abnormal gait, abnormality in thinking, agitation, altered sense of smell, amnesia, anxiety, ataxia, chills, confusion, depression, disorientation, dizziness, drowsiness, dysphoria, euphoria, fatigue, hallucination, headache, hypertonia, hypoesthesia, hypothermia, insomnia, irritability, lack of concentration, lethargy, malaise, mental status changes, migraine, nervousness, neuropathy, paranoia, paresthesia, restlessness, sedation, speech disturbance, stupor, vertigo, withdrawal syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, cellulitis, decubitus ulcer, diaphoresis, erythema, exfoliation of skin (application site, transdermal device), hyperhidrosis, local papules (application site, transdermal device), night sweats, pallor, papule, pruritus, pustules (application site, transdermal device), skin rash, vesicobullous rash (application site, transdermal device)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration, hot flash, hypercalcemia, hyperglycemia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, abdominal pain, anorexia, constipation, decreased appetite, diarrhea, dysgeusia, dyspepsia, dysphagia (buccal tablet/film/sublingual spray), flatulence, gastritis, gastroenteritis, gastroesophageal reflux disease, gastrointestinal hemorrhage, gastrointestinal ulcer (gingival, lip, mouth; transmucosal use/nasal spray), gingival pain (buccal tablet), gingivitis (lozenge), glossitis (lozenge), hematemesis, intestinal obstruction, nausea, periodontal abscess (lozenge/buccal tablet), rectal pain, stomatitis (lozenge/buccal tablet/sublingual tablet/sublingual spray), tongue disease (sublingual tablet), vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Difficulty in micturition, dysuria, erectile dysfunction, mastalgia, urinary incontinence, urinary retention, urinary tract infection, urinary urgency, vaginal hemorrhage, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bruise, leukopenia, lymphadenopathy, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Ascites, increased serum alkaline phosphatase, increased serum AST, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Abscess</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Application site burning (transdermal device), application site discharge (transdermal device), application site edema (transdermal device), application site erythema (transdermal device), application site irritation, application site itching (transdermal device), application site pain, application site rash (transdermal device), application site vesicles (transdermal device)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, leg cramps, limb pain, myalgia, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blepharoptosis, blurred vision, diplopia, dry eye syndrome, strabismus, swelling of eye, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea, asthma, atelectasis, bronchitis, cough, dyspnea, dyspnea (exertional), epistaxis, flu-like symptoms, hemoptysis, hyperventilation, hypoventilation, hypoxia, laryngitis, nasal congestion (nasal spray), nasal discomfort (nasal spray), nasopharyngitis, pharyngitis, pharyngolaryngeal pain, pneumonia, postnasal drip (nasal spray), rhinitis, rhinorrhea (nasal spray), sinusitis, upper respiratory tract infection, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, wound healing impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Allergic dermatitis, anaphylactoid reaction, angina pectoris, bradycardia, bronchoconstriction, chest wall rigidity, clonus, cyanosis, drug dependence (physical and psychological; with prolonged use), eczema, esophageal stenosis, exfoliative dermatitis, fecal impaction, flushing, genitourinary tract spasm, gingival hemorrhage, gum line erosion, hematuria, hostility, hypoglycemia, hypogonadism (Brennan 2013; Debono 2011), impaired consciousness, local hemorrhage, local hypersensitivity reaction, localized infection, local tissue necrosis, loss of consciousness, muscle spasm, muscle twitching, nocturia, oliguria, pancytopenia, pleural effusion, polyuria, respiratory distress, seizure, sexual disorder, skin erosion, Stevens-Johnson syndrome, swelling, swollen tongue, tonic-clonic seizures, tooth loss, upper abdominal pain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170590\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis, hypersensitivity) to fentanyl or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for transdermal device (Ionsys): Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; gastrointestinal obstruction, including paralytic ileus (known or suspected); hypersensitivity to cetylpyridinium chloride (eg, Cepacol).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for transdermal patch (Duragesic): Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; gastrointestinal obstruction, including paralytic ileus (known or suspected); patients requiring short-term therapy, management of acute or intermittent pain, postoperative or mild pain; patients who are <b>not</b> opioid tolerant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for transmucosal buccal tablets (Fentora), buccal films (Onsolis), lozenges (Actiq), sublingual tablets (Abstral), sublingual spray (Subsys), intranasal (Lazanda): Significant respiratory depression (Actiq, Fentora only); acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; gastrointestinal obstruction, including paralytic ileus (known or suspected); acute or postoperative pain (including headache, migraine, or dental pain); patients who are <b>not</b> opioid tolerant; acute pain management in the emergency room.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindication (not in US labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Septicemia; severe hemorrhage or shock; local infection at proposed injection site; disturbances in blood morphology and/or anticoagulant therapy or other concomitant drug therapy or medical conditions which could contraindicate the technique of epidural administration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablets (Abstral): Severe bronchial asthma, chronic obstructive airway, or status asthmaticus; acute respiratory depression; hypercapnia; cor pulmonale; known or suspected mechanical GI obstruction (eg, bowel obstruction or strictures) or any diseases/conditions that affect bowel transit (eg, ileus of any type); suspected surgical abdomen (eg, acute appendicitis or pancreatitis); mild pain that can be managed with other pain medications; acute pain management other than breakthrough or postoperative pain (including headache or migraine, dental pain or emergency room use); acute alcoholism, delirium tremens, and convulsive disorders; severe CNS depression, increased cerebrospinal or intracranial pressure and head injury; concurrent use or use within 14 days of a monoamine oxidase (MAO) inhibitor; breastfeeding women; during labor and delivery; opioid-nontolerant patients (including patients on intermittent or as needed opioid dosing).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch: Hypersensitivity to other opioids; suspected surgical abdomen (eg, acute appendicitis, pancreatitis); known or suspected mechanical GI obstruction (eg, bowel obstruction, strictures) or any diseases/conditions that affect bowel transit (eg, ileus of any type); acute alcoholism, delirium tremens, and convulsive disorders; severe CNS depression, increased cerebrospinal or intracranial pressure and head injury; concurrent use of MAO inhibitors or within 14 days of therapy; perioperative pain; women who are nursing, pregnant, or during labor and delivery</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transmucosal buccal tablets (Fentora): Hypersensitivity to other opioids; acute pain management in the emergency room; known or suspected mechanical GI obstruction (eg, bowel obstruction or strictures) or any diseases/conditions that affect bowel transit (eg, ileus of any type); suspected surgical abdomen (eg, acute appendicitis or pancreatitis); acute or severe bronchial asthma, chronic obstructive airway, status asthmaticus; acute respiratory depression; hypercapnia; cor pulmonale; acute alcoholism, delirium tremens, and convulsive disorders; severe CNS depression, increased cerebrospinal or intracranial pressure and head injury; concurrent use or use within 14 days of an MAO inhibitor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Documentation of allergenic cross-reactivity for opioids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170571\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: <b>[US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur, including following use in opioid non-tolerant patients and improper dosing. Monitor closely for respiratory depression, especially during initiation or dose escalation.</b> Abstral, Actiq, Duragesic, Fentora, Lazanda, Onsolis, or Subsys should only be prescribed for opioid-tolerant patients. Risk of respiratory depression usually occurs after administration of initial dose in nontolerant patients or when given with other drugs that depress respiratory function. Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: May occur with concomitant use of serotonergic agents (eg, SSRIs, SNRIs, triptans, TCAs), lithium, St John&rsquo;s wort, agents that impair metabolism of serotonin (eg, MAO inhibitors), or agents that impair metabolism of tramadol (eg, CYP2D6 and 3A4 inhibitors). Monitor patients for symptoms of serotonin syndrome such as mental status changes (eg, agitation, hallucinations, coma); autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia); neuromuscular changes (eg, hyperreflexia, incoordination); and/or GI symptoms (eg, nausea, vomiting, diarrhea).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan, 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergic rhinitis: Intranasal: Allergic rhinitis is not expected to alter fentanyl absorption following nasal administration; however, use of nasal decongestants (eg, oxymetazoline) during episodes of rhinitis may result in lower peak concentrations and delayed T<sub>max</sub>, therefore, titration of intranasal fentanyl is not recommended during use of nasal decongestants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis; may cause constriction of sphincter of Oddi.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia: Use with caution in patients with bradycardia or bradyarrhythmias (may produce further bradycardia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression/coma: Avoid use in patients with impaired consciousness or coma as these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delirium tremens: Use with caution in patients with delirium tremens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Avoid transdermal (patch) in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Use with caution in patients who are morbidly obese.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral mucositis: Sublingual spray (Subsys): Cancer patients with oral mucositis experienced increased fentanyl exposure following sublingual spray administration; avoid use in patients with grade 2 or higher mucositis; use with caution in patients with grade 1 mucositis, and closely monitor for respiratory and CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Use with caution in patients with toxic psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Avoid transdermal (patch) in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with a history of seizure disorders; may cause or exacerbate seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep-disordered breathing: Use opioids with caution for chronic pain and titrate dosage cautiously in patients with risk factors for sleep-disordered breathing, including HF and obesity. Avoid opioids in patients with moderate to severe sleep-disordered breathing (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzodiazepines or other CNS depressants: <b>[US Boxed Warning]: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of oxycodone/acetaminophen and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosage and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP3A4 interactions: <b>[US Boxed Warning]: The concomitant use of fentanyl with all cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in fentanyl plasma concentration. Monitor patients receiving fentanyl and any CYP3A4 inhibitor or inducer.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose. Use opioids for chronic pain with caution in this age group; monitor closely due to an increased potential for risks, including certain risks such as falls/fracture, cognitive impairment, and constipation. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increasing the risk for respiratory depression or overdose (Dowell [CDC 2016]). Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Neonatal withdrawal syndrome: <b>[US Boxed Warning]:</b> <b>Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. </b>Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. Onset, duration and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Buccal film, buccal tablet, intranasal, sublingual tablet, sublingual spray, and lozenge:<b> [US Boxed Warning]: Preparations contain an amount of medication that can be fatal to children. Keep all used and unused products out of the reach of children at all times and discard products properly.</b> Patients and caregivers should be counseled on the dangers to children including the risk of exposure to partially-consumed products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: IV: Inject slowly over 1 to 2 minutes; rapid IV infusion may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest; nondepolarizing skeletal muscle relaxant may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transmucosal (buccal film/tablet, sublingual spray/tablet, lozenge) and intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Transmucosal and nasal fentanyl formulations are contraindicated in the management of acute or postoperative pain and in opioid nontolerant patients.</b> Should be used only for the care of opioid-tolerant cancer patients with breakthrough pain and is intended for use by specialists who are knowledgeable in treating cancer pain.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Substantial differences exist in the pharmacokinetic profile of fentanyl products that result in clinically important differences in the extent of absorption of fentanyl. When prescribing or dispensing fentanyl, do not convert patients on a mcg-per-mcg basis from one fentanyl product to another fentanyl product; the substitution of one fentanyl product for another fentanyl product may result in a fatal overdose.</b> <b>Death has been reported in children who have accidentally ingested transmucosal immediate-release fentanyl products. Strict adherence to the recommended handling and disposal instructions is of the utmost importance to prevent accidental exposure.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Available only through the TIRF REMS ACCESS program, a restricted distribution program with outpatients, prescribers who prescribe to outpatients, pharmacies (inpatient and outpatient), and distributor-required enrollment.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Application site reactions, ranging from paresthesia to ulcerations and bleeding, occurred with buccal tablet (Fentora).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal iontophoretic system (Ionsys):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Ionsys REMS Program.</b> <b>Healthcare facilities that dispense Ionsys must be certified in this program and comply with the REMS requirements.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>- [US Boxed Warning]: For use only in patients in the hospital. Discontinue treatment before patients leave the hospital. Only the patient should activate Ionsys dosing. Accidental exposure to an intact Ionsys device or to the hydrogel component, especially by children, can result in a fatal overdose of fentanyl.</b> Following accidental contact with the device or its components, immediately rinse the affected area thoroughly with water. Do not use soap, alcohol, or other solvent because they may enhance the drug&rsquo;s ability to penetrate the skin; monitor for signs of respiratory or CNS depression. If the device is not handled correctly using gloves, healthcare professionals are at risk of accidental exposure to a fatal overdose of fentanyl.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Ionsys device is considered magnetic resonance unsafe. The device contains metal parts and must be removed and properly disposed of before an MRI procedure to avoid injury to the patient and damage to device. It is unknown if exposure to an MRI procedure increases release of fentanyl from the device. Monitor any patients wearing the device with inadvertent exposure to an MRI for signs of CNS and respiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Use of Ionsys device during cardioversion, defibrillation, X-ray, CT, or diathermy can damage the device from the strong electromagnetic fields set up by these procedures. The device contains radio-opaque components and may interfere with an X-ray image or CT scan. Remove and properly dispose of the device prior to cardioversion, defibrillation, X-ray, CT, or diathermy. Avoid contact with synthetic materials (such as carpeted flooring) to reduce the possibility of electrostatic discharge and damage to the device. Avoid exposing the device to electronic security systems to reduce the possibility of damage. Use near communications equipment (eg, base stations for radio telephones and land mobile radios, amateur radio, AM and FM radio broadcast and TV broadcast Radio) and Radio Frequency Identification (RFID) transmitters can damage the device. Depending on the rated maximum output power and frequency of the transmitter, the recommended separation distance between the device and communications equipment or the RFID transmitter ranges between 0.12 and 23 meters. The low-level electrical current provided by the device does not result in electromagnetic interference with other electromechanical devices like pacemakers or electrical monitoring equipment. If exposure to the procedures listed above, electronic security systems, electrostatic discharge, communications equipment, or RFID transmitters occurs, and if the device does not appear to function normally, remove and replace with a new device.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Topical skin reactions (erythema, sweating, vesicles, papules/pustules) may occur with use and are typically limited to the application site area. If a severe skin reaction is observed, remove device and discontinue further use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal patch:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Transdermal patch is contraindicated for use as an as-needed analgesic, in acute or postoperative pain, or in patients who are opioid nontolerant. Monitor closely for respiratory depression during use, particularly during initiation of therapy or after dose increases.</b> Should only be prescribed by health care professionals who are knowledgeable in the use of potent opioids in the management of chronic pain.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Exposure of application site and surrounding area to direct external heat sources (eg, heating pads, electric blankets, heat or tanning lamps, sunbathing, hot baths, hot tubs, heated water beds, saunas) may increase fentanyl absorption and has resulted in fatalities.</b> <b>Warn patients to avoid exposing the application site and surrounding area to direct external heat sources.</b> Serum fentanyl concentrations may increase by approximately one-third for patients with a body temperature of 40&deg;C (104&deg;F) secondary to a temperature-dependent increase in fentanyl release from the patch and increased skin permeability.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <b>[US Boxed Warning]: Deaths due to a fatal overdose of fentanyl have occurred when children and adults were accidentally exposed to fentanyl transdermal patch. Strict adherence to recommended handling and disposal instructions is necessary to prevent accidental exposures.</b> Avoid unclothed/unwashed application site exposure, inadvertent person-to-person patch transfer (eg, while hugging), incidental exposure (eg, sharing same bed, sitting on patch), intentional exposure (eg, chewing), or accidental exposure by caregivers when applying/removing patch.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Should be applied only to intact skin. Use of a patch that has been cut, damaged, or altered in any way may result in overdosage. Patients who experience adverse reactions should be monitored for at least 24 hours after removal of the patch. Drug continues to be absorbed from the skin for 24 hours or more following removal of the patch. May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion:<b> [US Boxed Warning]: Use exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient&rsquo;s risk prior to prescribing fentanyl and monitor all patients regularly for the development of these behaviors and conditions.</b> Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Other factors associated with increased risk include younger age and psychotropic medication use. Consider offering naloxone prescriptions in patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (&ge;50 morphine milligram equivalents/day orally), and concomitant benzodiazepine use (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental exposure: <b>[US Boxed Warning]: Accidental ingestion of even one dose, especially by children, can result in a fatal overdose of fentanyl. Fentanyl must be kept out of reach of children.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Chronic pain (outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder) in outpatient setting in adults: Opioids should not be used as first-line therapy for chronic pain management (pain &gt;3-month duration or beyond time of normal tissue healing) due to limited short-term benefits, undetermined long-term benefits, and association with serious risks (eg, overdose, MI, auto accidents, risk of developing opioid use disorder). Preferred management includes nonpharmacologic therapy and nonopioid therapy (eg. NSAIDs, acetaminophen, certain anticonvulsants and antidepressants). If opioid therapy is initiated, it should be combined with nonpharmacologic and non-opioid therapy, as appropriate. Prior to initiation, known risks of opioid therapy should be discussed and realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks. Therapy should be initiated at the lowest effective dosage using immediate-release opioids (instead of extended-release/long-acting opioids). Risk associated with use increases with higher opioid dosages. Risks and benefits should be re-evaluated when increasing dosage to &ge;50 morphine milligram equivalents (MME)/day orally; dosages &ge;90 MME/day orally should be avoided unless carefully justified (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Opioids decrease bowel motility; monitor for decreased bowel motility in postop patients receiving opioids. Use with caution in the perioperative setting; individualize treatment when transitioning from parenteral to oral analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Concurrent use of mixed agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms. Taper dose gradually when discontinuing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820032\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Opioid withdrawal may occur after conversion of one dosage form to another or after dosage adjustment; with prolonged use, taper dose to prevent withdrawal symptoms. Neonates who receive a total fentanyl dose &gt;1.6 mg/kg or continuous infusion duration &gt;5 days are more likely to develop opioid withdrawal symptoms; for infants and children 1 week to 22 months of age, those who receive a total dose of 1.5 mg/kg or duration &gt;5 days have a 50% chance of developing opioid withdrawal and those receiving a total dose &gt;2.5 mg/kg or duration of infusion &gt;9 days have a 100% chance of developing withdrawal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Dosage form specific:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Use transdermal patch in pediatric patients only if they are opioid-tolerant, receiving at least 60 mg oral morphine equivalents per day, and &ge;2 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Use of Actiq was evaluated in a clinical trial of 15 opioid-tolerant pediatric patients (age: 5 to 15 years) with breakthrough pain; 12 of the 15 patients received doses of 200 mcg to 600 mcg; no conclusions about safety and efficacy could be drawn due to the small sample size.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170653\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170576\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13298&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): May decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Agonists: May decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.<b> Exceptions: </b>Midodrine; Naphazoline (Ophthalmic); Phenylephrine (Ophthalmic); Phenylephrine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alvimopan: Opioid Analgesics may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May enhance the analgesic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiplatelet Agents (P2Y12 Inhibitors): FentaNYL may diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). FentaNYL may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Opioids (Anilidopiperidine) may enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): Opioids (Anilidopiperidine) may enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Opioids (Anilidopiperidine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of Opioid Analgesics. Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: May increase the serum concentration of FentaNYL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of FentaNYL.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of FentaNYL.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of FentaNYL. Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of FentaNYL. Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Opioid Analgesics may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diuretics: Opioid Analgesics may enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Opioid Analgesics may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of FentaNYL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: FentaNYL may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of FentaNYL. Management: Avoid fentanyl during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: FentaNYL may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: May diminish the therapeutic effect of Opioid Analgesics. Management: Avoid the concomitant use of nalmefene and opioid analgesics. Discontinue nalmefene 1 week prior to any anticipated use of opioid analgesics. If combined, larger doses of opioid analgesics will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids.  See full drug interaction monograph for detailed recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of FentaNYL. Management: Monitor for increased opioid effects/toxicities if these agents are combined. Consider using lower initial doses of fentanyl. Canadian labeling recommends avoidance of this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Analgesics. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Opioid Analgesics may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Opioid Analgesics may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Opioid Analgesics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of FentaNYL.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: May enhance the bradycardic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170606\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Fentanyl concentrations may be increased by grapefruit juice. Management: Avoid concurrent intake of large quantities (&gt;1 quart/day) of grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170578\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170593\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in some animal reproduction studies. Fentanyl crosses the placenta.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Fentanyl injection may be used for the management of pain during labor (ACOG 2002). When used for pain relief during labor, opioids may temporarily affect the heart rate of the fetus (ACOG 2002). Transient muscular rigidity has been observed in the neonate with fentanyl; symptoms of respiratory or neurological depression were not different than those observed in infants of untreated mothers.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>[US Boxed Warning]: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. </b>If chronic opioid exposure occurs in pregnancy, adverse events in the newborn (including withdrawal) may occur; monitoring of the neonate is recommended. The minimum effective dose should be used if opioids are needed (Chou 2009). Symptoms characteristic of neonatal abstinence syndrome have been observed following chronic fentanyl use in pregnant women. Neonatal abstinence syndrome following opioid exposure may present with autonomic (eg, fever, temperature instability), gastrointestinal (eg, diarrhea, vomiting, poor feeding/weight gain), or neurologic (eg, high-pitched crying, increased muscle tone, irritability, seizure, tremor) symptoms (Dow 2012; Hudak 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction or infertility (Brennan 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Transdermal patch (Duragesic), transdermal iontophoretic system (Ionsys), transmucosal lozenge (Actiq), intranasal (Lazanda), sublingual tablet (Abstral), sublingual spray (Subsys), buccal tablet (Fentora), and buccal film (Onsolis) are not recommended for analgesia during labor and delivery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052733\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory rate, blood pressure, heart rate, oxygen saturation, bowel sounds, abdominal distention; signs of misuse, abuse, or addiction; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch: Monitor patient for at least 24 hours after application of first dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chronic pain (long-term therapy outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder): Evaluate benefits/risks of opioid therapy within 1 to 4 weeks of treatment initiation and with dose increases. Re-evaluate benefits/risks every 3 months during therapy or more frequently in patients at increased risk of overdose or opioid use disorder. Urine drug testing is recommended prior to initiation and re-checking should be considered at least yearly (includes controlled prescription medications and illicit drugs of abuse). State prescription drug monitoring program (PDMP) data should be reviewed by clinicians prior to initiation and periodically during therapy (frequency ranging from every prescription to every 3 months) (Dowell [CDC 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170570\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds with stereospecific receptors at many sites within the CNS, increases pain threshold, alters pain reception, inhibits ascending pain pathways</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170589\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 3 to 12 years: Intranasal: 5 to 10 minutes (Borland 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Analgesic: IM: 7 to 8 minutes; IV: Almost immediate (maximal analgesic and respiratory depressant effects may not be seen for several minutes); Transdermal patch (initial placement): 6 hours; Transmucosal: 5 to 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: IM: 1 to 2 hours; IV: 0.5 to 1 hour; Transdermal (removal of patch/no replacement): Related to blood level; some effects may last 72 to 96 hours due to extended half-life and absorption from the skin, fentanyl concentrations decrease by ~50% in 20 to 27 hours; Transmucosal: Related to blood level; respiratory depressant effect may last longer than analgesic effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal, patch: Initial application: Drug is released at a nearly constant rate from the transdermal matrix system into the skin, where it accumulates; this results in a depot of fentanyl in the outer layer of skin. Fentanyl is absorbed into systemic circulation from the depot. This results in a gradual increase in serum concentration over the first 12 to 24 hours, followed by fairly constant concentrations for the remainder of the dosing interval. Absorption is decreased in cachectic patients (compared to normal size patients). Exposure to external heat increases drug absorption from patch.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal, device: At the activation of each dose, an electrical current is activated for 10 minutes, which moves a dose of fentanyl from the drug-containing reservoir through the skin and into the systemic circulation. Fentanyl concentrations increase slowly with device activation and continue to increase for ~5 minutes after the completion of each 10 minute dose. Absorption of fentanyl from the device increases as a function of time and is independent of frequency of dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transmucosal, buccal tablet and buccal film: Rapid, ~50% from the buccal mucosa; remaining 50% swallowed with saliva and slowly absorbed from GI tract.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transmucosal, lozenge: Rapid, ~25% from the buccal mucosa; 75% swallowed with saliva and slowly absorbed from GI tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Highly lipophilic, redistributes into muscle and fat; <b>Note:</b> IV fentanyl exhibits a 3-compartment distribution model. Changes in blood pH may alter ionization of fentanyl and affect its distribution between plasma and CNS</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>dss</sub>: Children: 0.05 to 14 years of age (after long-term continuous infusion): ~15 L/kg (range: 5 to 30 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>dss</sub>: Adults: 4 to 6 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 79% to 87%, primarily to alpha-1 acid glycoprotein; also binds to albumin and erythrocytes; <b>Note:</b> Free fraction increases with acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, primarily via CYP3A4 by N-dealkylation (to norfentanyl) and hydroxylation to other inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: <b>Note:</b> Comparative studies have found the buccal film to have a 40% greater systemic exposure (ie, AUC) than the transmucosal lozenge, and the buccal tablet to have a 30% to 50% greater exposure than the transmucosal lozenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal film: 71% (mucositis did not have a clinically significant effect on C<sub>max</sub> and AUC; however, bioavailability is expected to decrease if film is inappropriately chewed and swallowed)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal tablet: 65%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lozenge: ~50%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual spray: 76%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablet: 54%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients 5 months to 4.5 years: 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients 6 months to 14 years (after long-term continuous infusion): ~21 hours (range: 11-36 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 2 to 4 hours; when administered as a continuous infusion, the half-life prolongs with infusion duration due to the large volume of distribution (Sessler 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal device: Terminal: ~16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch: 20 to 27 hours (apparent half-life is influenced by continued fentanyl absorption from skin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transmucosal products: 3 to 14 hours (dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: 15 to 25 hours (based on a multiple-dose pharmacokinetic study when doses are administered in the same nostril and separated by a 1-, 2-, or 4-hour time lapse)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal film: ~14 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal tablet: 100-200 mcg: 3 to 4 hours; 400 to 800 mcg: 11 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal film: 0.75 to 4 hours (median: 1 hour)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buccal tablet: 20 to 240 minutes (median: 47 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lozenge: 20 to 480 minutes (median: 20 to 40 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: Median: 15 to 21 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual spray: 10 to 120 minutes (median: 90 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablet: 15 to 240 minutes (median: 30 to 60 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch: 20 to 72 hours; steady state serum concentrations are reached after two sequential 72-hour applications</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine 75% (primarily as metabolites, &lt;7% to 10% as unchanged drug); feces ~9%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Newborn infants: Clearance may be significantly correlated to gestational age and birth weight (Saarenmaa 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15597829\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma concentrations with transdermal use were approximately twice as high in pediatric patients 1.5 to 5 years of age, who are not opioid-tolerant, compared with adults. Pharmacokinetic parameters in older pediatric patients were similar to those seen in adults. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5989383\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Subsys Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (1): $70.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (1): $93.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (1): $141.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (1): $188.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (1): $234.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1200 (600 X 2) mcg (2): $376.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1600 (800 X 2) mcg (2): $469.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lozenge</b> (Actiq Buccal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (1): $68.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (1): $87.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (1): $106.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (1): $126.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1200 mcg (1): $164.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1600 mcg (30): $6,076.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lozenge</b> (FentaNYL Citrate Buccal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (30): $564.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (30): $714.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (30): $875.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (30): $1,037.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1200 mcg (30): $1,348.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1600 mcg (30): $1,663.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Ionsys Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg/ACT (1): $240.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 72-hour</b> (Duragesic-100 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/hr (5): $958.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 72-hour</b> (Duragesic-12 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mcg/hr (5): $214.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 72-hour</b> (Duragesic-25 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg/hr (5): $258.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 72-hour</b> (Duragesic-50 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/hr (5): $473.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 72-hour</b> (Duragesic-75 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg/hr (5): $722.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 72-hour</b> (FentaNYL Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mcg/hr (5): $101.51</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg/hr (5): $72.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5 mcg/hr (5): $326.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/hr (5): $131.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">62.5 mcg/hr (5): $474.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg/hr (5): $201.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">87.5 mcg/hr (5): $646.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/hr (5): $267.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FentaNYL Citrate (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/2 mL (2 mL): $1.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg/5 mL (5 mL): $2.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500MCG/10ML (10 mL): $3.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mcg/20 mL (20 mL): $10.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500 mcg/50 mL (50 mL): $21.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FentaNYL Citrate (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500 mcg/50 mL (50 mL): $34.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FentaNYL Citrate-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/100 mL 0.9% (100 mL): $17.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25MG/250ML 0.9% (250 mL): $26.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/100 mL 0.9% (100 mL): $32.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FentaNYL Citrate-NaCl Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1MG/250ML 0.9% (250 mL): $25.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FentaNYL Citrate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5MG/250ML 0.9% (250 mL): $39.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5MG/250ML 0.9% (250 mL): $64.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250MCG/50ML 0.9% (50 mL): $20.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lazanda Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/ACT (1): $1,038.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/ACT (1): $1,450.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg/ACT (1): $1,656.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Cartridge</b> (FentaNYL Citrate (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/2 mL (2 mL): $2.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (FentaNYL Citrate (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/2 mL (2 mL): $4.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (FentaNYL Citrate-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15MCG/3ML 0.9% (3 mL): $5.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MCG/5ML 0.9% (5 mL): $11.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500MCG/50ML 0.9% (50 mL): $16.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Abstral Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (32): $1,678.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (32): $2,107.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg (32): $2,527.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (32): $3,040.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (32): $3,916.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (32): $4,790.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Fentora Buccal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (1): $59.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (1): $74.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (28): $3,030.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (28): $3,933.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (28): $4,846.38</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170596\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abstral (BM, ES, GB, HR, IE, PH, QA, TR);</li>\n      <li>Acref (JP);</li>\n      <li>Actiq (AU, CH, DE, DK, ES, FI, FR, GB, IE, IL, KR, PT, SE);</li>\n      <li>Adolor (CZ);</li>\n      <li>Breakyl (CZ, GB, LV);</li>\n      <li>Denpax (AU);</li>\n      <li>Dolforin (BG, CZ, LV);</li>\n      <li>Durasic (BD);</li>\n      <li>Durogesic (AE, AU, BH, CN, CO, CY, EG, ES, ID, IN, JO, KW, LB, LK, MX, NZ, PH, PK, PY, QA, SA, SG, TH, VN);</li>\n      <li>Durogesic D Trans (HK, KR, PE, TW);</li>\n      <li>Durogesic D-Trans (BR);</li>\n      <li>Durotep MT (JP);</li>\n      <li>Dyurohezik (UA);</li>\n      <li>Effentora (EE, ES, GB, IE, MT);</li>\n      <li>Fantamax (SG);</li>\n      <li>Fencino (GB);</li>\n      <li>Fent (LK);</li>\n      <li>Fenta (IL);</li>\n      <li>Fentaderm Patch (KR);</li>\n      <li>Fentadermal (PH);</li>\n      <li>Fentadur Patch (KR);</li>\n      <li>Fentalis (GB, IE);</li>\n      <li>Fentamax Mat Patch (KR);</li>\n      <li>Fentanest (BR, IT, MX, PY, UY);</li>\n      <li>Fentanila (CL);</li>\n      <li>Fentanilo (CU, VE);</li>\n      <li>Fentanyl (CR, DO, GT, NI, PA, SV);</li>\n      <li>Fentanyl Citrate (EC);</li>\n      <li>Fentax (PY);</li>\n      <li>Fentora (HK);</li>\n      <li>Fentos Tape (JP);</li>\n      <li>Filtaten (MX);</li>\n      <li>Instanyl (AT, BE, CZ, DE, DK, EE, ES, FR, HR, IS, LT, LU, MT, NL, PL, SE, SI, SK);</li>\n      <li>Instanyl Nasal (GB, NO);</li>\n      <li>Ionsys (AT, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PT, RU, SE, SK, TR);</li>\n      <li>Leptanal (SE);</li>\n      <li>Lunaldin (LV);</li>\n      <li>Matrifen (BE, DK, EE, GB);</li>\n      <li>Mezolar Matrix (GB);</li>\n      <li>Oncolis (BM);</li>\n      <li>One Duro (JP);</li>\n      <li>Opifen (BD);</li>\n      <li>Opiodur (GB);</li>\n      <li>Osmanil (GB);</li>\n      <li>PecFent (GB);</li>\n      <li>Pentyl (BD);</li>\n      <li>Recivit (GB);</li>\n      <li>Sublimaze (AR, AU, GB, IE, NZ, PH, ZA);</li>\n      <li>Tanyl (IL);</li>\n      <li>Trofentyl (IN, PH);</li>\n      <li>Vellofent (RO);</li>\n      <li>Verfen (LK);</li>\n      <li>Victanyl (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abstral (fentanyl) [prescribing information]. Lake Oswego, OR: Galena Biopharma Inc; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Actiq (fentanyl) [prescribing information]. Fraiser, PA: Cephalon Inc; December 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists Number 36, July 2002. Obstetric Analgesia and Anesthesia,&quot; <i>Obstet Gynecol</i>, 2002, 100(1):177-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/12100826/pubmed\" target=\"_blank\" id=\"12100826\">12100826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Pain Society (APS). &quot;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&quot; 6th ed. Glenview, IL: American Pain Society, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anand KJ and International Evidence-Based Group for Neonatal Pain, &ldquo;Consensus Statement for the Prevention and Management of Pain in the Newborn,&rdquo; <i>Arch Pediatr Adolesc Med</i>, 2001, 155(2):173-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/11177093/pubmed\" target=\"_blank\" id=\"11177093\">11177093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arnold JH, Truog RD, Scavone JM, et al. Changes in the pharmacodynamics response to fentanyl in neonates during continuous infusion. <i>Journal of Pediatrics</i>. 1991;119:639-643.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/1919898/pubmed\" target=\"_blank\" id=\"1919898\">1919898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barash PG, Cullen BF, Stoelting RK, et al, eds. <i>Clinical Anesthesia</i>, 6th ed, Philadelphia, PA; Lippincott Williams &amp; Wilkins, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. <i>Crit Care Med</i>. 2013;41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berde CB, Sethna NF. Analgesics for the treatment of pain in children. <i>N Engl J Med</i>. 2002;347(14):1094-1103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/12362012/pubmed\" target=\"_blank\" id=\"12362012\">12362012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Billmire DA, Neale HW, and Gregory RO, &ldquo;Use of I.V. Fentanyl in the Outpatient Treatment of Pediatric Facial Trauma,&rdquo; <i>J Trauma</i>, 1985, 25(11):1079-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/4057297/pubmed\" target=\"_blank\" id=\"4057297\">4057297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borland M, Jacobs I, King B, et al, &quot;A Randomized Controlled Trial Comparing Intranasal Fentanyl to Intravenous Morphine for Managing Acute Pain in Children in the Emergency Department,&quot; <i>Ann Emerg Med</i>, 2007, 49(3):335-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/17067720/pubmed\" target=\"_blank\" id=\"17067720\">17067720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borland ML, Bergesio R, Pascoe EM, et al, &quot;Intranasal Fentanyl Is an Equivalent Analgesic to Oral Morphine in Paediatric Burns Patients for Dressing Changes: A Randomised Double Blind Crossover Study,&quot; <i>Burns</i>, 2005, 31(7):831-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/16005154 /pubmed\" target=\"_blank\" id=\"16005154 \">16005154 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borland ML, Jacobs I, and Geelhoed G, &quot;Intranasal Fentanyl Reduces Acute Pain in Children in the Emergency Department: A Safety and Efficacy Study,&quot; <i>Emerg Med (Fremantle)</i>, 2002, 14(3):275-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/12487045/pubmed\" target=\"_blank\" id=\"12487045\">12487045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/23414717/pubmed\" target=\"_blank\" id=\"23414717\">23414717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chou R, Fanciullo GJ, Fine PG, et al, &quot;Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain,&quot;<i> J Pain</i>, 2009, 10(2):113-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/19187889/pubmed\" target=\"_blank\" id=\"19187889\">19187889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung S, Lim R, and Goldman RD, &quot;Intranasal Fentanyl Versus Placebo for Pain in Children During Catheterization for Voiding Cystourethrography,&quot; <i>Pediatr Radiol</i>, 2010, 40(7):1236-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/20180109 /pubmed\" target=\"_blank\" id=\"20180109 \">20180109 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cole J, Shepherd M, and Young P, &quot;Intranasal Fentanyl in 1-3-Year-Olds: A Prospective Study of the Effectiveness of Intranasal Fentanyl as Acute Analgesia,&quot;<i> Emerg Med Australas</i>, 2009, 21(5):395-400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/19840089/pubmed\" target=\"_blank\" id=\"19840089\">19840089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cramton RE, Gruchala NE. Managing procedural pain in pediatric patients. <i>Curr Opin Pediatr</i>. 2012;24(4):530-538.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/22732639/pubmed\" target=\"_blank\" id=\"22732639\">22732639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crellin D, Ling RX, and Babl F, &quot;Does the Standard Intravenous Solution of Fentanyl (50 microg/mL) Administered Intranasally Have Analgesic Efficacy?&quot; <i>Emerg Med Australas</i>, 2010, 22(1):62-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/20152004/pubmed\" target=\"_blank\" id=\"20152004\">20152004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. <i>MMWR Recomm Rep</i>. 2016;65(1):1-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/26987082/pubmed\" target=\"_blank\" id=\"26987082\">26987082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dow K, Ordean A, Murphy-Oikonen J, et al, &quot;Neonatal Abstinence Syndrome Clinical Practice Guidelines For Ontario,&quot; <i>J Popul Ther Clin Pharmacol</i>, 2012, 19(3):e488-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/23241498/pubmed\" target=\"_blank\" id=\"23241498\">23241498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duragesic (fentanyl transdermal system) [prescribing information]. Titusville, NJ: Janssen; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fentora (fentanyl) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Finn M and Harris D, &quot;Intranasal Fentanyl for Analgesia in the Paediatric Emergency Department,&quot; <i>Emerg Med J</i>, 2010, 27(4):300-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/20385685 /pubmed\" target=\"_blank\" id=\"20385685 \">20385685 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gomar C and Fernandez C, &ldquo;Epidural Analgesia-Anaesthesia in Obstetrics,&rdquo; <i>Eur J Anaesthesiol</i>, 2000, 17(9):542-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/11029122/pubmed\" target=\"_blank\" id=\"11029122\">11029122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grass JA. NPatient-controlled analgesia. <i>Anesth Analg</i>. 2005;101(5 Suppl):S44-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/16334492/pubmed\" target=\"_blank\" id=\"16334492\">16334492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121:433-443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herd D and Borland M, &quot;Intranasal Fentanyl Paediatric Clinical Practice Guidelines,&quot;<i> Emerg Med Australas</i>, 2009, 21(4):335.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/19682022/pubmed\" target=\"_blank\" id=\"19682022\">19682022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hudak ML, Tan RC, Committee On Drugs, et al, &quot;Neonatal Drug Withdrawal,&quot; <i>Pediatrics</i>, 2012, 129(2):e540-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/22291123/pubmed\" target=\"_blank\" id=\"22291123\">22291123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP), &quot;Standard Concentrations of Neonatal Drug Infusions,&quot; <i>ISMP</i>, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ionsys (fentanyl transdermal system) [prescribing information]. Parsippany, NJ: The Medicines Company; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz R, Kelly HW, and Hsi A, &ldquo;Prospective Study on the Occurrence of Withdrawal in Critically Ill Children Who Receive Fentanyl by Continuous Infusion,&rdquo; <i>Crit Care Med</i>, 1994, 22(5):763-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/8181283/pubmed\" target=\"_blank\" id=\"8181283\">8181283</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kornick CA, Santiago-Palma J, Khojainova N, Primavera LH, Payne R, Manfredi PL. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. <i>Cancer.</i> 2001;92(12):3056-3061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/11753984/pubmed\" target=\"_blank\" id=\"11753984\">11753984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krauss B, Green SM. Procedural sedation and analgesia in children. <i>Lancet</i>. 2006;367(9512):766-780.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/16517277/pubmed\" target=\"_blank\" id=\"16517277\">16517277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar P, Denson SE, Mancuso TJ. Clinical report &ndash; premedication for nonemergency endotracheal intubation in the neonate.<i> Pediatrics</i>. 2010;125:608-615.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/20176672/pubmed\" target=\"_blank\" id=\"20176672\">20176672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lazanda (fentanyl citrate spray) [prescribing information]. Newark, CA: Depomed Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee HA and Anderson PO, &ldquo;Giving Partial Doses of Transdermal Patches,&rdquo; <i>Am J Health Syst Pharm</i>, 1997, 54(15):1759-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/9262751/pubmed\" target=\"_blank\" id=\"9262751\">9262751</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leuschen MP, Willett LD, Hoie EB, et al, &ldquo;Plasma Fentanyl Levels in Infants Undergoing Extracorporeal Membrane Oxygenation,&rdquo; <i>J Thorac Cardiovasc Surg</i>, 1993, 105(5):885-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/8487566/pubmed\" target=\"_blank\" id=\"8487566\">8487566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lim S, Paech MJ, Sunderland VB, et al, &ldquo;Pharmacokinetics of Nasal Fentanyl,&rdquo; <i>J Pharm Pract Res</i>, 2003, 33:59-63.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu LL and Gropper MA, &ldquo;Postoperative Analgesia and Sedation in the Adult Intensive Care Unit,&rdquo; <i>Drugs</i>, 2003, 63(8):755-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/12662124/pubmed\" target=\"_blank\" id=\"12662124\">12662124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manjushree R, Lahiri A, Ghosh BR, et al, &quot;Intranasal Fentanyl Provides Adequate Postoperative Analgesia in Pediatric Patients,&quot; <i>Can J Anaesth</i>, 2002, 49(2):190-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/11823399/pubmed\" target=\"_blank\" id=\"11823399\">11823399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD. <i>Miller&rsquo;s Anesthesia.</i> 7th ed, Philadelphia PA: Churchill Livingstone, 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, Academy Of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. <i>Breastfeed Med</i>. 2012;7(6):547-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Onsolis (fentanyl buccal soluble film) [prescribing information]. Canton, MA: Collegium Pharmaceutical; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pang WW, Huang S, Chung YT, et al, &ldquo;Comparison of Intravenous Retention of Fentanyl and Lidocaine on Local Analgesia in Propofol Injection Pain,&rdquo; <i>Acta Anaesthesiol Sin</i>, 1997, 35(4):217-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/9553237/pubmed\" target=\"_blank\" id=\"9553237\">9553237</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. <i>Anesthesiology</i>. 1999;90(2):576-599.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/9952166/pubmed\" target=\"_blank\" id=\"9952166\">9952166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &quot;Standardizing I.V. Infusion Concentrations: National Survey Results,&quot; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roth B, Schlunder C, Houben F, et al, &ldquo;Analgesia and Sedation in Neonatal Intensive Care Using Fentanyl by Continuous Infusion,&rdquo; <i>Dev Pharmacol Ther</i>, 1991, 17(3-4):121-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/1841826/pubmed\" target=\"_blank\" id=\"1841826\">1841826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saarenmaa E, Neuvonen PJ, and Fellman V, &ldquo;Gestational Age and Birth Weight Effects on Plasma Clearance of Fentanyl in Newborn Infants,&rdquo; <i>J Pediatr</i>, 2000, 136(6):767-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/10839874 /pubmed\" target=\"_blank\" id=\"10839874 \">10839874 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saunders M, Adelgais K, and Nelson D, &quot;Use of Intranasal Fentanyl for the Relief of Pediatric Orthopedic Trauma Pain,&quot; <i>Acad Emerg Med</i>, 2010, 17(11):1155-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/21175512/pubmed\" target=\"_blank\" id=\"21175512\">21175512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schechter NL, Weisman SJ, Rosenblum M, et al, &ldquo;The Use of Oral Transmucosal Fentanyl Citrate for Painful Procedures in Children,&rdquo; <i>Pediatrics</i>, 1995, 95(3):335-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/7862469/pubmed\" target=\"_blank\" id=\"7862469\">7862469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sessler CN, Varney K. Patient-focused sedation and analgesia in the ICU. <i>Chest</i>. 2008;133(2):552-565.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/18252923/pubmed\" target=\"_blank\" id=\"18252923\">18252923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spigset O and Hagg S, &ldquo;Analgesics and Breast-feeding: Safety Considerations,&rdquo; <i>Paediatr Drugs</i>, 2000, 2(3):223-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/10937472/pubmed\" target=\"_blank\" id=\"10937472\">10937472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Subsys (fentanyl spray) [prescribing information]. Chandler, AZ: Insys Therapeutics; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Toussaint S, Maidl J, Schwagmeier R, et al, &quot;Patient-Controlled Intranasal Analgesia: Effective Alternative to Intravenous PCA for Postoperative Pain Relief,&quot; <i>Can J Anaesth</i>, 2000, 47(4):299-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/10764171/pubmed\" target=\"_blank\" id=\"10764171\">10764171</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). <i>WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses</i>. 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/23720867/pubmed\" target=\"_blank\" id=\"23720867\">23720867</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeltzer LK, Altman A, Cohen D, et al, &ldquo;Report of the Subcommittee on the Management of Pain Associated With Procedures in Children With Cancer,&rdquo; <i>Pediatrics</i>, 1990, 86(5 Pt 2):826-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/2216645 /pubmed\" target=\"_blank\" id=\"2216645 \">2216645 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13298 Version 219.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50847583\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708780\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F170610\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F170611\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1052734\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442526\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1052726\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F170583\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F170567\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F28106456\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F170661\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F50183666\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874432\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1052739\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Neonatal\" href=\"#F14472638\" class=\"outlineLink\">Usual Infusion Concentrations: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472637\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F170604\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1052738\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F170670\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F170667\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F170590\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F170571\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820032\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F170653\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F170576\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F170606\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F170578\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F170593\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1052733\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F170570\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F170589\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F15597829\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5989383\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F170596\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13298|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">Fentanyl: Drug information</a></li><li><a href=\"topic.htm?path=fentanyl-patient-drug-information\" class=\"drug drug_patient\">Fentanyl: Patient drug information</a></li></ul></div></div>","javascript":null}